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Visceral leishmaniasis (VL) caused by Leishmania donovani and Leishmania infan-
tum/chagasi represents the secondmost challenging infectious diseaseworldwide, leading
to nearly 500,000 new cases and 60,000 deaths annually. Zoonotic VL caused by L. infan-
tum is a re-emergent canid zoonoses which represents a complex epidemiological cycle
in the New world where domestic dogs serve as a reservoir host responsible for poten-
tially fatal human infection and where dog culling is the only measure for reservoir control.
Life-long immunity to VL has motivated development of prophylactic vaccines against the
disease but very few have progressed beyond the experimental stage. No licensed vaccine
is available till date against any form of leishmaniasis. High toxicity and increasing resis-
tance to the current chemotherapeutic regimens have further complicated the situation in
VL endemic regions of the world. Advances in vaccinology, including recombinant proteins,
novel antigen-delivery systems/adjuvants, heterologous prime-boost regimens and strate-
gies for intracellular antigen presentation, have contributed to recent advances in vaccine
development againstVL. Attempts to develop an effective vaccine for use in domestic dogs
in areas of canine VL should be pursued for preventing human infection. Studies in animal
models and human patients have revealed the pathogenic mechanisms of disease pro-
gression and features of protective immunity.This review will summarize the accumulated
knowledge of pathogenesis, immune response, and prerequisites for protective immunity
against humanVL. Authors will discuss promising vaccine candidates, their developmental
status and future prospects in a quest for rational vaccine development against the disease.
In addition, several challenges such as safety issues, renewed and coordinated commit-
ment to basic research, preclinical studies and trial design will be addressed to overcome
the problems faced in developing prophylactic strategies for protection against this lethal
infection.
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INTRODUCTION
Leishmaniases are a wide spectrum of parasitic diseases caused by
dimorphic protozoan ﬂagellates of the genus Leishmania. These
obligatory parasites of host macrophages are transmitted by ∼30
different species of phlebotomine sandﬂies (Pearson and Sousa,
1996). Leishmaniasis accounts for global morbidity of 2.4 millions
(946,000 for males and 1,410,000 for females) and a mortality rate
of approximately 60,000 per year1. Among the three clinical pat-
terns of leishmaniasis (cutaneous, mucocutaneous, and visceral),
visceral leishmaniasis (VL) is the most severe in terms of symp-
toms and clinical complications. Of the 500,000 new cases of VL
every year, 90% occur in Bangladesh, Brazil, India, Ethiopia,Kenya
and Sudan, countries that are strongly related to poverty (Hotez
et al., 2004; Alvar et al., 2006). India alone accounts for more than
half of the annual global VL infections, which is rapidly emerging
as an important opportunistic HIV-coinfection.
Based on transmission characteristics, there are two types ofVL:
zoonotic VL caused by Leishmania infantum, and anthroponotic
VL or kala-azar caused by Leishmania donovani. Kala-azar is
1http://www.who.int/tdr/disease/leish/direction.htm
a systemic infection clinically characterized by prolonged fever,
profound cachexia, hepatosplenomegaly, hypergammaglobuline-
mia, and pancytopenia, with an incubation period varying
between 2 and 6 months (Bray, 1976; Chappuis et al., 2007).
Almost all clinically symptomatic patients die within months if
left untreated. Moreover, 5–10% of cured individuals from VL
in India and 50% in Sudan may also develop cutaneous mani-
festations in the form of macular, maculo-papular, and nodular
skin lesions containing parasites, termed as post-kala-azar dermal
leishmaniasis (PKDL). PKDL represents an important yet unclear
issue of parasite persistence and the putative reservoir for kala-
azar between epidemic cycles that need special attention for VL
eradication (Addy and Nandy, 1992; Dereure et al., 2003).
In India the few therapeutic options registered for kala-azar
include pentavalent antimonials (sodium stibogluconate), liposo-
mal/free amphotericin B, miltefosine, and paromomycin. How-
ever, all have one or more limitations or insufﬁciencies in the
long run. Growing resistance to pentavalent antimonials, prohib-
itive cost of the available lipid formulations of amphotericin B,
toxicity, need for hospitalization, HIV-coinfection, and increasing
reports of relapse, have made the global demand for VL vac-
cine a major public health priority. Life-long immunity against
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reinfection indicates feasibility of successful vaccination against
VL. However, no anti-leishmanial vaccine is still available for
human use. Considerable inter-speciﬁc diversity of lipophospho-
glycan (LPG) structure, extraordinary host evasive mechanism of
the parasite and heterogeneity of human population (Beverley and
Turco, 1998; Kaye and Scott, 2011) represent unprecedented chal-
lenges for VL vaccinology. Absence of an in vivo animal model
accurately reﬂecting the clinical features of human VL adds to
limitations of development of immunoprophylaxis against VL.
However, current advances in genome sequencing and biotech-
nology have created a thrust for VL vaccinology an area which
has been neglected for years. Development of a cross-protective
anti-Leishmania vaccine is thus a desirable public health goal to
combat this lethal infection.
Till date vaccine research against VL can be divided into three
main groups: vaccinationwith live virulent or killed parasites (ﬁrst
generation vaccines), vaccination with whole-cell lysates/puriﬁed
fractions, subunit vaccination with native/recombinant parasite
proteins (second-generation vaccines), andplasmidDNAandviral
vector based vaccines encoding parasite virulence factors (third
generation vaccines). Recent concepts include use of genetically
modiﬁed live-attenuated Leishmania parasites, and proteomics
approach for the search of a cross-protective leishmanial vaccine
that would ideally protect against both cutaneous and visceral
forms of the disease.
IMMUNOPATHOLOGY OF HUMAN VL: IMPLICATIONS FOR
VACCINE DESIGN
The clinical manifestations of leishmaniasis are determined not
only by the parasite species but also by the general health and
genetic constitution of the host (Bogdan et al., 1996; D’Oliveira
Júnior et al., 1997). Understanding the immunological changes
that are associated with resistance and susceptibility to the disease
are fundamental to both designing as well as evaluating outcome
of vaccines. Although mouse models have been used for study of
both cutaneous and VL, very little is known about human VL.
Clinical studies reveal that humanVL has a complex immunol-
ogy characterized by mixed T-helper-1 (Th1)/T-helper-2 (Th2)
cell milieu, where a suppressed Th1 response along with an ele-
vated Th2 is the hallmark of the active disease. Conversely, pro-
tective immunity is achieved by upregulation of Th1 response
after a successful chemotherapy (Hailu et al., 2001; Kubar and
Fragaki, 2005). The crucial step in generating anti-leishmanial
immunity is maintenance of the proportion of CD4+ and CD8+
T cells that results in secretion of different cytokines required
for immunomodulation in VL. Patients with kala-azar demon-
strate negative delayed type hypersensitivity and non-proliferative
response to parasite antigens (Sacks et al., 1987; Dominguez et al.,
2002). Most of the T cell clones from the PBMCs of the active
VL patients and asymptomatic subjects (seropositive and DTH
positive) are CD8+ with negligible CD4+, while the situation is
reversed in the cured individuals with more numbers of CD4+
than CD8+ cells (Saha et al., 2006). Probably, the CD4+ T cells are
lost prior to CD8+ cells in VL, thus a depressed CD4:CD8 ratio
has been observed in patients compared with controls (Rohtagi
et al., 1996; Clarêncio et al., 2009). Associated upregulation of
immunosuppressive CD4+CD25+ regulatory T cells (Treg) in
active VL patients probably leads to parasite persistence and
chronic infection (Saha et al., 2007).
Cellular immunity is considered to be the keymediator of resis-
tance by means of IFN-γ that induces microbicidal activity against
both the promastigotes and amastigote forms of L. donovani, in an
H2O2-dependent (Murray and Cartelli, 1983; Murray et al., 1983)
and NO-mediated pathway (Vouldoukis et al., 1997) for parasite
clearance (Badaro et al., 1990; Badaro and Johnson, 1993; Harms
et al., 1993; Squires et al., 1993; Sundar et al., 1994, 1995, 1997a,b;
Sundar and Murray, 1995). Probably, impaired macrophage func-
tions due to lack of detectable inducible NO synthase mRNA
activity in liver and spleen fastens the disease progression in L.
donovani infected hamsters, closely resembling the situation in
human VL (Melby et al., 2001a). IL-12 is an immunoregulatory
cytokine for initiation and maintenance of the Th1 response and
plays an important role in the induction of IFN-γ production by
T and NK cells (Kobayashi et al., 1989; Stern et al., 1990; Scharton
and Scott, 1993; Trinchieri, 1993). In VL patients, IL-12 enhances
Th1 responses and restores lymphocyte proliferative responses,
IFN-γ production and cytotoxic responses (Ghalib et al., 1995;
Bacellar et al., 1996). TNF-α is a proinﬂammatory chemokine
associatedwith bothprotection and susceptibility to leishmaniasis.
When produced at very high levels, TNF-α might have a disease-
enhancing effect (Karplus et al., 2002). IL-4, considered to be a
marker of Th2 response, is present in the sera, PBMC supernatant
(Zwingenberger et al., 1990; Sundar et al., 1997a) and as mRNA
in active VL (Carvalho et al., 1994; Kenney et al., 1998). Although
largely implicated in disease exacerbation (Zwingenberger et al.,
1990), beneﬁcial role of IL-4 in driving Th1 immunity for early
protection against VL has also been suggested (Kamogawa et al.,
1993; Alexander et al., 2000). IL-10 primarily down-modulates
innate as well as acquired immune response. Moreover, IL-10
induction by host IgG-opsonized amastigotes leads to immune
suppression of Th1 response with downregulation of IL-12 for
disease progression (Caldas et al., 2005). Patients with VL have
increased expression of mRNA for IL-10 in bone marrow and
lymph nodes with enhanced levels of IL-10 in sera and leishmanial
antigen-stimulated PBMC supernatants (Saha et al., 2007). Imbal-
anced IL-10 production may be associated with disease progres-
sion to PKDL (Ghalib et al., 1993; Saha et al., 2007). Transforming
growth factor-β (TGF-β) having immunosuppressive properties, is
also documented in leishmaniasis disease progression (Nylén and
Akuffo, 2009; Donaghy et al., 2010). A high level of total TGF-β
affects NO production by deactivating macrophages both in vitro
and in vivo (Barral-Netto et al., 1992; Li et al., 1999). Recent stud-
ies have linked IL-13 (Babaloo et al., 2001), IL-15 (Carson et al.,
1994, 1995; Armitage et al., 1995; Jullien et al., 1997; Milano et al.,
2002), IL-17 and IL-22 (Pitta et al., 2009)with protection against L.
donovani. IL-27, produced mainly by macrophages and DC, regu-
lates Th17 cells thereby maintaining a balance between immunity
and pathology in human VL (Anderson et al., 2009; Murugaiyan
et al., 2009). Enhanced IL-27 in VL patients is shown to induce
IL-21 which in turn promotes expansion of IL-10 secreting T
cells, leading to parasite multiplication in spleen (Ansari et al.,
2011).
Together with phagocytes, NK cells represent the ﬁrst line of
defense against pathogens by two principal mechanisms, cytolytic
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destruction of infected cells, and secretion of proinﬂammatory
cytokines (e.g., IFNγ, TNFα; Nylén et al., 2003). Activated NK
cells promote DC maturation along with clearance of autologous
immatureDCs (Akuffo et al., 1993; Piccioli et al., 2002). Compara-
tively lower frequency of NKcells in activeVL than controls further
conﬁrms their role in healing (Nylén et al., 2007). Conversely, DCs
are pivotal in initiating and orchestrating the immune response
by phagocytosis, antigen presentation, and cytokine production
(Banchereau and Steinman, 1998; Mellman and Steinman, 2001).
DCs essentially guide resistance or susceptibility to Leishmania
by driving the differentiation and proliferation of CD4+ T cells
toward one of the two polarized pathogen-speciﬁc Th1 or Th2
phenotype (Moser and Murphy, 2000). Differential roles of DC–
NK cell cross-talk at various stages of Leishmania infection present
new insight on the interactions between innate immune compo-
nents during infection with this parasite (Sanabria et al., 2008).
Exploitation of DC biology may thus be a rationale of VL vaccine
design for better antigen-delivery and presentation.
Although elevated levels of anti-leishmanial antibodies IgG,
IgM, IgE, and IgG subclasses are well documented in active VL
(Atta et al., 1998; Anam et al., 1999a,b; da Matta et al., 2000; Ryan
et al., 2002; Ravindran et al., 2004), their precise role in protection
against Leishmania is controversial and needs to be reappraised.
IFN-γ probably upregulates IgG1 and IgG3, while IL-4 and IL-
5 stimulate the production of high levels of IgG, IgM, IgE, and
IgG subclasses like IgG4 in humans (Ozbilge et al., 2006). How-
ever, antibodies are not relevant for vaccine-induced protection
in the absence of an appropriate cellular response. Overall, both
CD4+ and CD8+ T cells are required to mediate parasite control
and successful vaccination requires IL-12 driven IFN-γ-dependent
Th1/Th2mixed response againstVL.However,high IL-4 and IL-10
production in immunized animals, despite very high IFN-γ, may
lead to vaccine failure and disease exacerbation in VL (Bhowmick
et al., unpublished data).
COMPLEXITY OF HOST–PARASITE INTERACTION
Leishmania spp. had been widely regarded as fastidious, oblig-
ate intracellular pathogens primarily inhabiting macrophages. But
recent studies have conﬁrmed their presence in hematopoietic
cells having a common myeloid precursor (i.e., neutrophils, resi-
dent macrophages, dermal DCs, inﬂammatory monocyte-derived
DCs) (Gueirard et al., 2008) and non-hematopoietic cells such
as ﬁbroblasts. Survival of Leishmania within the mammalian
host depends on its ability to evade and manipulate the anti-
leishmanial immune response to establish infection (Bogdan and
Rollinghoff, 1998). Despite the presentation of leishmanial anti-
gens and the initiation of inﬂammatory responses, Leishmania
can reside within the host tissues for long periods of time by
exploiting several evasive mechanisms (Zambrano-Villa et al.,
2002). Opsonization of Leishmania promastigotes with parasite-
speciﬁc IgG facilitates their uptake bymacrophages andDCswhich
leads to establishment of infection (Prina et al., 2004). IL-12 pro-
duced by parasite-engulfed DCs, as a signature of anti-Leishmania
protective response, is counteracted by immunosuppressive IL-10
produced by parasitized macrophages that activates host Treg cells
leading to disease progression (Woelbing et al., 2006). Notably
LPG, the most abundant molecule constituting the glycocalyx
of Leishmania promastigotes, plays an important role in the
interactions between the parasite and the sandﬂy promoting the
infectivity of the parasites. Considerable diversity in LPG structure
among different Leishmania spp. explains their vector speciﬁcity
(Sacks, 2001) and may also affect their immunological properties.
Thus, LPG which is a virulence factor allowing safe passage and
survival of metacyclic promastigotes in macrophages in L. major
(Späth et al., 2000) and L. donovani (Desjardins and Descoteaux,
1997; Lodge et al., 2006; Vinet et al., 2009), has no such role in L.
mexicana (Ilg, 2000). Profound differences in the virulence factors
of L. major and L. donovani also affect their consequent patholo-
gies as well as underlying immune evasive mechanisms, making
development of a cross-protective vaccine difﬁcult. Sandﬂy saliva
itself can also act as a virulence factor by enhancing invasion of
macrophages by promastigotes, even with low-dose inoculations
(Gillespie et al., 2000). In fact, Leishmania has evolved numerous
strategies to interfere with a broad range of macrophage signal-
ing that includes protein kinase C, the JAK2/STAT1 cascade, and
the MAP kinase pathway that favor its survival and persistence
in host cells (Shadab and Ali, 2011). Recruitment of inhibitory
CD4+CD25+FoxP3+ regulatory T cells (Treg) (Engwerda et al.,
2004; Peters and Sacks, 2006; Nylén et al., 2007), inhibition of
macrophage phagosomal maturation (interfering with fusion of
phagosomes and lysosomes) (Olivier et al., 2005), and inhibition
of DC maturation and chemotaxis (Brandonisio et al., 2004) are
some of the strategies employed by Leishmania to evade effector
mechanisms of the host immune system. Maturation of human
monocyte-derived DCs is inhibited by both L. donovani and L.
amazonensis (Favali et al., 2007; Tejle et al., 2008). Further, deple-
tion of CD8+ T-cell following infection with L. donovani may
contribute to chronic infection (Joshi et al., 2009). Thus, the
main goal of Leishmania vaccinology is establishment of a Th1-
dominated cell-mediated response along with CD8+ T cells for
sustained protective immunity (Scott, 2003).
Though it is often assumed that the type of disease depends
solely on Leishmania species, susceptibility or resistance to leish-
maniasis markedly varies within and between genetically diverse
human populations (Walton and Valverde, 1979; Momeni and
Aminjavaheri, 1994; Weigle and Saravia, 1996; Sharma et al.,
2000; Bucheton et al., 2002). For example, PKDL is inﬂuenced
by genetic polymorphism in IFN-γ receptor (Mohamed et al.,
2003), and susceptibility is linked to polymorphism in IL-4 gene
in Sudanese patients (Blackwell et al., 2005). Natural resistance-
associated macrophage protein-1 (NRAMP1) has been shown to
increase the risk of acquiring infection. In mice, Nramp1/Slc11a1
Lsh locus on chromosome 1 is responsible for acute susceptibility
to L. donovani (Demant et al., 1996). However, its role in human
is not clear. This difference is probably due to the fact that the
Lsh/Nramp1/Slc11a1 allele in susceptible mice practically abol-
ishes the gene function (equivalent to a traditional knockout),
whereas polymorphisms in the promoter, exon 3 and the intron of
human SLC11A1 are expected to have less inﬂuence on susceptibil-
ity to L. donovani (Bucheton et al., 2003; Mohamed et al., 2004).
Polymorphisms in genes coding HLA class I and class II mole-
cules have been relatedwith susceptibility to L. guyanensis (Barbier
et al., 1987) and L. braziliensis (Lara et al., 1991; Petzl-Erler et al.,
1991) although impact of these polymorphisms on VL species
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seems ambiguous (Bucheton et al., 2003). Recent genome-wide
linkage study from Sudan and Brazil has identiﬁed a putative sus-
ceptibility locus DLL1 (Delta-like 1 for Notch3) which is strongly
implicated as the chromosome 6q27 VL susceptibility gene (Faki-
ola et al., 2011). In brief, further understanding of the complex yet
unique species-speciﬁc virulence mechanisms, immunogenetics,
and clinical correlates is needed for early diagnosis, customized
chemotherapeutic strategies, and prophylaxis against VL.
PROGRAMMING OF INNATE IMMUNITY
The role of innate immune system comprising of macrophages,
DCs, NK cells, and granulocytes forming the primary defense
mechanism against pathogen, is gaining increasing attention in
curingVL. Innate immune system is activated via pattern recogni-
tion receptors (PRRs) on host macrophages and DCs that recog-
nize conserved pathogen-associated molecular patterns (PAMPs)
of microbes. Activation of PRRs like Toll-like receptors (TLRs),
nucleotide-binding domain (NOD)-like receptors and scavenger
receptors by PAMPs leads tomaturation and trafﬁcking of theDCs
to local lymph nodes for antigen presentation to naive T cells rais-
ing the adaptive immunity against the invading pathogen (Kaisho
and Akira, 2000, 2001; Bocarsly et al., 2002). Again the pattern of
TLR expression varies between the APC subsets and their anatom-
ical locations (Banchereau and Steinman, 1998). Secretion of
proinﬂammatory cytokines and chemokines following TLR acti-
vation contribute to Th1-independent immediate defense mecha-
nisms (Hayashi et al., 2003). Bypassing these natural innatemecha-
nisms by Leishmania promastigotes probably marks the beginning
of successful parasitism. Leishmania adopts apparently quiescent
mechanisms of macrophage entry with slow or negligible stimula-
tion of NF-κβ pathway which appears to be true for all Leishmania
spp., thus delaying adaptive response. This has been experimen-
tally evidenced in mice receiving low-dose parasite challenge in
the ear (Belkaid et al., 2000). Plethora of evidence suggests a cru-
cial role of TLR:PAMP interaction for bridging innate and adaptive
immunity. Past experiencewith vaccine success of leishmanization
(consisting of live virulent parasites) as against reduced protec-
tion by killed vaccines can possibly be assumed due to loss of
parasite PAMPs during inactivation process which is required for
establishing future adaptive immunity. To alleviate this problem,
subunit or genetic vaccines are often adjuvantedwithTLR-agonists
for innate triggering of adaptive immunity to elicit robust cel-
lular and humoral response. TLR ligands that mimic PAMPs to
activate immune cells via Toll-like receptors (TLRs) are being
developed for clinical use and immunotherapy against a variety
of diseases. Adjuvant success of several TLR-agonists like CpG-
DNA (immunostimulatory oligodeoxynucleotides):TLR9 agonist,
MPL (Monophosphoryl Lipid) A and GLA (Glucopyranosyl Lipid
Adjuvant): TLR4 agonists, and imiquimod: TLR7 agonist, have
been well documented against Leishmania (Buates and Mat-
lashewski, 1999; Walker et al., 1999; Reed et al., 2003; Coler et al.,
2007). Synthetic imidazoquinoline compounds (i.e., imiquimod
and resiquimod) have been shown to activate human TLR7 and
8 (Gibson et al., 2002; Hemmi et al., 2002), and TLR7 in mice.
TLR3 and TLR4 in synergy with TLR7, TLR8, and TLR9 in human
and mouse DCs boost up Th1 response through increased pro-
duction of IL-12 and IL-23. TLR synergy further establish DCs
unidirectional intracellular cross-talk to acquire T cell response to
a given vaccine in MyD88-dependent manner (Kang et al., 2002;
Martinon and Tschopp, 2005; Napolitani et al., 2005; Zhu et al.,
2008). Combinatorial synergy of MPL with CpG in L110f vaccine
has shown to improve immunotherapy against murine CL proba-
bly resulting from chemokineRANTES (regulated upon activation
normal T cell expressed and secreted) expression thereby recruit-
ing activated T cells to the site of infection with enhanced IL-12
production (Raman et al., 2010). Future vaccination strategies
using live non-virulent or genetically altered parasites with TLR
7/8 or TLR 4 agonists can be appropriate combination for prim-
ing innate immunity for durable, broad spectrum cross-protection
against Leishmania. Designing of such novel multicomponent
adjuvants combining TLRs and/or non-TLRs with vaccines for
better ampliﬁcation of T-cell and B-cell response merits further
study.
ANIMAL MODELS FOR VL
Among several models tried for L. donovani, BALB/c mice and
Syrian golden hamsters (Mesocricetus auratus) are the most exten-
sively studied animalmodels for primary screening of vaccines and
drugs.Absenceof functionalSc11 1a1 locus inBALB/c andC57BL6
mice renders them susceptible to L. donovani infection compared
to resistant CBA mice possessing functional Sc11 1a1gene that
confers innate anti-leishmanial immunity (Bradley, 1974; Black-
well, 1996). Unlike L. major infection, Th1/Th2 dichotomy in
cytokine milieu is not evident during murine VL caused by L.
donovani/chagasi. The protective immunity in murineVL primar-
ily depends on IL-12 driven Th1 response leading to increased IL-2
and IFN-γ production for parasite killing. Substantial upregula-
tion of inducible NO synthase (iNOS, NOS2) by IFN-γ generates
NO from splenic and liver macrophages thereby controlling par-
asite multiplication in these organs (Green et al., 1990; Blackwell,
1996). TGF-β, IL-10, and IL-13 are the major disease promoting
cytokines leading to suppression of Th1 response (Wilson et al.,
2005). Low levels of IL-4 usually enhance vaccine-induced protec-
tion by increasing IFN-γ production from CD8+ T cells (Stäger
et al., 2003) and subsequently play no role in disease exacerbation
in L. donovani infected mice. Despite the wide usage of the mouse
model for vaccine studies inVL, this does not resemble the clinical
outcomes seen in fatal human VL. Murine VL is largely subclin-
ical and self-resolving disease compared to disseminated visceral
infectionwhich seems to be a major limitation in extrapolating the
results to humanVL. In mice, clearance of hepatic parasite burden
occurs after 2 weeks post infection due to efﬁcient granuloma for-
mation resulting from interaction of Leishmania-speciﬁc T cells
with parasitized dendritic cells and resident macrophages. Parasite
killing in mature granulomas leads to resolution of hepatic infec-
tion in about 56 days in experimental VL. Hence, vaccine efﬁcacy
and disease progression in mice can be predicted from the degree
of maturation of hepatic granulomas in challenged animals corre-
lating with cell-mediated immunity (Murray et al., 1992; Carrión
et al., 2006). In contrast to liver, spleen, and bonemarrow act as the
site of parasite persistence resulting in chronic infection in mice.
The failure of parasitized marginal zone macrophages of spleen to
produce IL-12,breakdownof splenic architecture and lack of gran-
ulomatous reaction leads to high parasite burden in spleen (Nieto
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et al., 2011). Infecting mice with large inoculums can thus be more
suitable to resemble pathological changes similar to active human
VL (Carrión et al., 2006). Interestingly, inoculating BALB/c mice
with Indian L. donovani strains like AG83 leads to progressive VL
with clinical manifestations of hepatosplenomegaly, at least up to
6 months post infection (Mazumder et al., 2004; Bhowmick et al.,
2009). The disease progression in this model is associated with
suppressed Th1 response due reduced IFN-γ and IL-12 produc-
tion from spleen cells along with enhanced IL-4 and IL-10, which
get reversed with vaccine-induced protection. Further, infected
mice also demonstrate high TGF-β and low TNF-α 4 months post
infection resulting in impairedNO-mediated parasite clearance by
macrophages (Bhowmick et al., 2009). However, precise correlates
of pathology and protection are yet to be deﬁned for this model
for development of successful intervention against human VL.
Compared to mice, hamsters seem to a better model for pro-
gressive VL expressing clinical features like hepatosplenomegaly,
immunosuppression, anemia, cachexia, and death, closely simu-
lating human VL. Impaired macrophage activation in liver and
spleen due to lack of NOS2 expression throughout disease pro-
gression seems to be the major cause of uncontrolled parasite
multiplication and death in hamster (Melby et al., 2001a). High
levels of TGF-β have also been reported in tissues and cultured
immune cells from mice and hamsters infected with L. donovani
and L. chagasi, suggesting its deﬁnitive role in disease exacerba-
tion (Müller et al., 1992; Gomes et al., 2000; Gantt et al., 2003).
Increased secretion of TNF-αduring later stage of disease probably
results in profound weight loss in infected hamsters (Tracey et al.,
1988). However, inadequacy of immunological reagents limits the
use of hamster model for prophylactic and therapeutic analy-
sis of VL. High innate susceptibility of hamsters to L. donovani
makes them a more suitable model for studying immunopathol-
ogy of VL than evaluation of protective immunity. Among several
higher non-human primate models of VL, Indian langur mon-
key (Presbytis entellus) has shown consistent and progressive VL
similar to active human disease. Immune protection achieved by
autoclavedL. donovani (ALD) alongwithBCG in thismodel corre-
lates with high IFN-γ, IL-2, and lymphoproliferation (Dube et al.,
1998; Misra et al., 2001). Difﬁculties in laboratory handling, non-
availability and expense are some of the drawbacks of primate
models that need to be solved for their routine use as VL models.
VL VACCINE DEVELOPMENT: CONVENTIONAL APPROACHES
FIRST GENERATION VACCINES
“Leishmanization,” the traditional practise of inoculating live, vir-
ulent Leishmania parasites from the exudates of a cutaneous lesion
is the only successful intervention against leishmaniasis and has
been practiced for centuries in Middle East and Russia with efﬁ-
cacy levels up to 100% (Nadim et al., 1983; Khamesipour et al.,
2005). Based on persistence of parasites in the primary inoculated
site for cellular response, leishmanization could confer virtually
life-long and complete protection which is of utmost importance
for developing anti-leishmanial vaccine. Unfortunately, features
of adaptive immunity elicited for successful leishmanization have
not been studied in human. It is known that previous exposure
to L. major can confer protection against subsequent VL (Zijlstra
et al., 1994). However, leishmanization trials have never been done
either against New World tegumentary leishmaniasis or human
VL. Although still practiced in Uzbekistan, severe side effects
and complications have eventually replaced it by ﬁrst generation
killed Leishmania vaccines, with or without adjuvants. In order to
improve safety of leishmanization, live L. major have been coin-
jectedwithCpG-DNAwithout compromising the vaccine potency
inmurinemodel (Mendez et al., 2003). Success of CpG adjuvanted
live vaccine in murine CL apparently depended on CD4 Th17 cells
and early recruitment of IFN-γ secreting CD4 cells at inoculation
site for long-term protection (Wu et al., 2010). This vaccine also
resulted in activation of dermal DCs and NK cells for enhanced
protection almost without any side effect unlike leishmanization.
Although effective against VL in several experimental models,
recent human clinical trials of killed vaccines have been found to
be safe but not as effective as leishmanization, having low efﬁcacies
(54%) when tested in humans (Shariﬁ et al., 1998; Momeni et al.,
1999; Armijos et al., 2004; Vélez et al., 2005) and dogs (Genaro
et al., 1996; Mohebali et al., 2004). The success of leishmanization
over killed vaccines in CL can possibly be explained by an in vitro
study evaluating human T cell function when simulated by live
vs. killed parasites (Nateghi Rostami et al., 2010). In addition to
increased IFN-γ from CD4+ T cells, live parasites could also stim-
ulate CD8+ T cells to secrete IFN-γ. Killed parasites, however,
could stimulate CD4+ T cells only. This probably accounts for
better immunologic memory leading to sustained immunity after
healing of live infections (Okwor and Uzonna, 2008; Nateghi Ros-
tami et al., 2010). Promising enough, a very recent approach have
generated a killed butmetabolically active L. infantum chagasi pro-
mastigotes after treating them with amotosalen and low-dose UV
radiation that resulted in replication-deﬁcient parasites that could
protect mice against experimental VL (Bruhn et al., 2012). These
parasite could enter host macrophages for initial transformation
for stimulating robust adaptive immunity for protection lasting
up to 6 weeks post infection. However, most clinical trials have
been conducted for CL with very few for VL (Khalil et al., 2000,
2006). The anticipated success with CL clinical trials may lead to a
few human VL trials due to the highly conserved genomes of the
Leishmania spp.
Ease of production, economy, and safety of ﬁrst generation
leishmanial vaccines have made them attractive for immunother-
apeutic strategy against VL. Combination therapy comprising of
alum-precipitated autoclaved L. major (ALM) with BCG has been
found to be protective in PKDL patients signiﬁcantly reducing
cases of relapse (Musa et al., 2008). Killed Leishmania vaccines
probably hold more prospects for immunotherapy combined with
drugs than their single use against VL which needs further human
trials.
SECOND-GENERATION VACCINES
Vaccination with Leishmania fractions
Partially or fully puriﬁed Leishmania subfractions have been
widely used in experimental models (Gradoni, 2001; Handman,
2001) owing to their excellent immunoprotective properties. Pre-
vious studies showed that vaccinationwith fucose-mannose ligand
(FML) protects against experimental VL in several animal mod-
els such as mice (Swiss Albino and BALB/c) and dog (Palatnik de
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Sousa et al., 1996; Santos et al., 1999, 2002; Parra et al., 2007).Addi-
tionally, membrane antigens of L. donovani promastigotes (LAg)
entrapped in cationic liposomes could induce signiﬁcant levels of
protection inmice andhamsters (Afrin andAli,1997;Ali andAfrin,
1997; Afrin et al., 2000, 2002). Soluble leishmanial antigen (SLA)
partially puriﬁed fraction from LAg, entrapped in cationic lipo-
somes show both prophylactic and therapeutic efﬁcacy against VL
(Bhowmick et al., 2007). Moreover, immunostimulatory sequence
bearing non-coding plasmid DNA co-entrapped in liposomal SLA
showed Th1 biased immune protection in BALB/c mice model
of VL (Mazumder et al., 2007). Recently, fraction (F2) of L.
donovani soluble promastigote antigen belonging to 97.4–68 kDa
has been identiﬁed for its ability to stimulate Th1-type cellular
responses in cured VL patients and hamsters (Garg et al., 2006).
Further fractionation of this F2-fraction revealed Th1-stimulatory
polyproteins ranging from 89.9 to 97.1 kDa that could offer long-
lasting protection against L. donovani in hamsters (Kumari et al.,
2008a,b). However, difﬁculties in large-scale production, stan-
dardization of in vitro culture conditions and puriﬁcation pro-
cedures are some of the issues raised regarding such vaccines to be
considered for clinical trials against VL.
Subunit protein vaccines
Following hundreds of native and recombinant antigens tested
inducing protection against CL, several molecularly deﬁned vac-
cine candidates have been evaluated against VL over the past two
decades (Table 1). LPG was the ﬁrst molecularly deﬁned vaccine
candidate against leishmaniasis that conferred protection against
CL (Handman andMitchell, 1985;McConville et al., 1987;Karanja
et al., 2011). Concurrent studies with L. donovani-derived LPG
suggested it as a promising candidate vaccine for transmission
blocking (Tonui et al., 2001). The ﬁrst recombinant antigen against
leishmaniasis was gp63 or leishmanolysin, conserved in all Leish-
mania species. Although highly protective in its native form, both
against CL (Kahl et al., 1990) and VL (Bhowmick et al., 2008),
recombinant gp63 (rgp63) expressed in E. coli system failed to
induce protection againstCL (Handman et al., 1990).However, the
reports remained controversial since BCG expressing gp63 showed
protection in susceptible mice against L. major challenge (Abdel-
hak et al., 1995) which revealed that immunogenicity of processed
peptides is not likely dependent upon its native structure. Addi-
tionally, recent reports of protection elicited by liposomal delivery
of rgp63 via subcutaneous route, both against L. major (Jaafari
et al., 2006, 2007) and L. donovani (Mazumder et al., 2011b)
validate the use of liposomes as a critical parameter in these vacci-
nation protocols. The high level of similarity in conserved residues
of GP63 among differentVL species: L. donovoni,L. chagasi, and L.
infantum has recently been authenticatedwhich suggests feasibility
of a GP63-based vaccine success against VL (Sinha et al., 2011).
Nuclear histone protein H2B is another highly conserved anti-
gen that is antigenic in several Leishmania species (Soto et al.,
1999; Chenik et al., 2006). Analysis of the H2B showed sequence
homology of carboxyl-terminal region among different Leishma-
nia species, ensuring cross-speciﬁc protection. A recent study
demonstrated that entire H2B protein is more efﬁcient than its
amino- or carboxyl-terminal in inducing a dominant Th1 proﬁle
that holds future against leishmaniasis (Meddeb-Garnaoui et al.,
2010). Considerable leishmanicidal properties (dose-dependent
killing promastigotes of L. amazonensis, L. major, L. braziliensis,
and L. mexicana) have also been demonstrated for histones H2A
and H2B (but not histone HI0) (Wang et al., 2011) which show
a new possibility of using these histone proteins for therapeutic
vaccinations against leishmaniasis.
Open reading frame (ORFF), is a single copy gene, located on
chromosome35 as a part of themultigene LD1 locus,preferentially
expressed in L. donovani amastigotes (Jain and Madhubala, 2008).
Puriﬁed recombinant ORFF protein has been partially protective
against L. donovani challenge in murine model (Tewary et al.,
2004b). More recently, ORFF expressed as a chimeric ubiquitin
conjugate was tested against antimony-sensitive and antimony-
resistant strains of L. donovani as a vaccine candidate. This study
demonstrated better protective efﬁcacy of ubiquitin-conjugated
ORFF than unconjugated one against experimental VL (Sharma
and Madhubala, 2009). Several other subunit protein vaccines
have been tested against different forms of leishmaniasis with
varying success. These include dp72 (Jaffe et al., 1990; Aguilar-Be
et al., 2005), ribosomal P0 protein (Iborra et al., 2005),Leishmania
elongation factor 2 (LelF-2) (Kushawaha et al., 2011), amastigote
cysteine proteases (Zadeh-Vakili et al., 2004), F14 (Bhardwaj et al.,
2009), hydrophilic acylated surface protein B1 (HASPB1) (Stager
et al., 2000), etc. The observation that some individuals exposed
to uninfected sandﬂy mount a protective response to Leishmania
(Davies andMazloumiGavgani, 1999) has lead to vaccine attempts
designed against sandﬂy salivary proteins or insect gut antigens
that can protect from infection (Morris et al., 2001). Recently,
hamsters immunized with LMJ 19, a novel 11kDa protein from
Lutzomya longipalpis saliva, were reported to be protected against
VL (Gomes et al., 2008).
The use of synthetic peptide vaccines, particularly the T-cell
epitopes also opened an interesting avenue in Leishmania vaccine
since 1980s (Lamb et al., 1984; Jardimet al., 1990;Russo et al., 1993;
Spitzer et al., 1999). However, this enthusiasm has waned in recent
times due to inadequate memory response and inability of all
individuals to respond to the peptide, which needs to be resolved.
Contrary to deﬁned single antigen, multicomponent or
polyprotein vaccines have been demonstrated to afford better pro-
tection against experimental VL. LEISH-F1 (formerly Leish111f),
consisting of three recombinant antigens: Leishmania elongation
initiation factor (LeIF), thiol-speciﬁc antioxidant (TSA), and L.
major stress-inducible protein-1 (LmSTI1) is such a polyprotein
vaccine that was able to confer protection against L. major (Skeiky
et al., 2002) and L. infantum (Coler et al., 2007). A crucial com-
ponent of LEISH-F1 vaccination is the selection of the adjuvant.
The vaccine remainedmost efﬁcaciouswhen co-administeredwith
IL-12, as well as detoxiﬁed derivative of lipid A from lipopolysac-
charide (LPS) of Salmonella Minnesota, lipid A formulated with
squalene in a stable emulsion (MPL-SE). LEISH-F1+MPL-SE is
the only second-generation vaccine that successfully cleared the
clinical trial for safety and immunogenicity againstVL (Vélez et al.,
2009; Chakravarty et al., 2011).
Subunit vaccines based on recombinant proteins and syn-
thetic peptides are safe. However, they are poor generators of
cytotoxic T-cell (CTL) responses (Lima et al., 2004) and no sin-
gle antigen could confer complete protection. To overcome this
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Table 1 | Second-generation vaccine candidates tested against L. donovani.
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
FML Native antigen+Saponin Hamster L. donovani Protection Palatnik de Sousa et al.
(1994a)
FML Native antigen+Saponin Mouse L. donovani Protection Palatnik de Sousa et al.
(1994b)
FML Native antigen+Saponin/Aluminum
hydroxide
Mouse L. donovani Protection Santos et al. (1999)
FML Native antigen+ IL-12/BCG/saponin Mouse L. donovani Protection Santos et al. (2002)
FML Native antigen+Quill A Dog L. donovani Protection Borja-Cabrera et al. (2002)
FML Native antigen+Saponin Mouse L. donovani Protection Santos et al. (2002)
FML Native antigen+Saponin Mouse L. donovani Protection Palatnik de Sousa et al.
(2004)
LAg Native antigen entrapped in cationic
liposome
Mouse/Hamster L. donovani Protection Afrin and Ali (1997), Ali and
Afrin (1997)
LAg Native antigen entrapped in negatively
charged liposome
Mouse L. donovani Partial protection Afrin et al. (2000)
LAg Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Mazumder et al. (2004)
LAg Native antigen entrapped in liposomes Mouse L. donovani Protection Bhowmick et al. (2010)
LAg Native antigen+BCG/MPL/entrapped
in liposomes
Mouse L. donovani Protection Ravindran et al. (2010)
SLA Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick et al. (2007)
SLA Native antigen+non-coding pDNA
co-entrapped in cationic liposome
Mouse L. donovani Protection Mazumder et al. (2007)
SLA Native antigen entrapped in cationic
liposome+MPL
Mouse L. donovani Protection Ravindran et al. (2012)
gp36 Native antigen+Saponin Mouse L. donovani Protection Paraguai de Souza et al.
(2001)
SA Native antigen+CpG-ODN Mouse L. donovani Protection Tewary et al. (2004a)
LD 31, 51, 72, 91 Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick and Ali (2009)
gp70-2/dp72 Native antigen+Corynebacterium
parvum
Mouse L. donovani Partial protection Jaffe et al. (1990)
Hsp70+Hsp83 Native antigen+MPL/ALD Mouse L. donovani Protection Kaur et al. (2011b)
gp63+Hsp70 Native antigen Mouse L. donovani Protection Kaur et al. (2011a)
LPG Native antigen+BCG Mouse/Hamster L. donovani No protection Tonui et al. (2001)
78 kDa Native antigen Mouse L. donovani Protection Mukherjee et al. (2002)
78 kDa Native
antigen+MPL/ALD/liposome/FCA
Mouse L. donovani Protection Nagill and Kaur (2010)
dp72 Native antigen Mouse L. donovani/L. major Cross-protection Rachamim and Jaffe (1993)
gp63 Native antigen entrapped in cationic
liposome
Mouse L. donovani Protection Bhowmick et al. (2008)
A2 Recombinant
antigen+Propionibacterium acnes
Mouse L. donovani Protection Ghosh et al. (2001b)
HASPB1 Recombinant antigen+ IL-12 Mouse L. donovani Protection Stager et al. (2000)
gp63 Recombinant antigen+S. typhimurium Mouse L. donovani/L. major Cross- protection McSorley et al. (1997)
gp63 Recombinant antigen entrapped in
cationic liposome+MPL-TDM
Mouse L. donovani Protection Mazumder et al. (2011a)
F14 Recombinant antigen+MPL Hamster L. donovani Protection Bhardwaj et al. (2009)
Leishmune Recombinant antigen Dog L. donovani Protection Nogueira et al. (2005)
Leishmune Recombinant antigen Dog L. donovani Partial protection Saraiva et al. (2006)
(Continued)
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Table 1 | Continued
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
ORFF+BT1 Recombinant antigen Mouse L. donovani Partial protection Dole et al. (2000)
ORFF Recombinant antigen+CpG-ODN Mouse L. donovani Partial protection Tewary et al. (2004b)
ORFF Recombinant antigen Mouse L. donovani Partial protection Tewary et al. (2005)
ORFF Recombinant antigen+ IL-12 DNA Mouse L. donovani Protection Tewary et al. (2005)
LdγGCS Recombinant antigen entrapped in NIV Mouse L. donovani Protection Henriquez et al. (2010)
LelF-2 Recombinant antigen Hamster L. donovani Protection Kushawaha et al. (2011)
BCG: Mycobacterium bovis Bacillus Calmette–Guerin; LPG, lipophosphoglycan; FML, fucose-mannose ligand; LdγGCS, L. donovani gamma-glutamyl cysteine syn-
thetase; LelF-2, L. donovani elongation factor-2; gp, glycoprotein; ORFF, open reading frame F; BT1, biopterin transporter; dp72, L. donovani promastigote antigen of
72 kDa; HASPB1, hydrophilic acylated surface protein B1; Hsp, heat-shock protein; LAg, leishmanial membrane antigen; NIV, non-ionic surfactant vesicle; CpG-ODN,
CpG oligodeoxynucleotides; ALD, autoclaved L. donovani.
inherent problem of subunit vaccines, several studies are being
carried out with promising adjuvants like Bacillus–Calmette–
Guerin (BCG), alum, saponin, liposomes, MPLA, and other TLR
ligands for vaccine success against VL (Bhowmick et al., 2008).
Long-term immunity generated by subcutaneous immunization
of liposomal soluble leishmanial antigen (SLA) with MPL-TDM
(monophosphoryl lipid–trehalose dicorynomycolate) in BALB/c
mice largely depends on high IFN-γ and CD8+ T cells, along
with downregulation of IL-4 (Ravindran et al., 2012). RAPSODI, a
human-compatible second-generation vaccine is currently under-
going preclinical trial heading toward a pan-Leishmania vaccine
(Rapsodi against leishmaniasis2; accessed 2 January 2012). Based
on the most immunodominant antigen, promastigote surface
antigen (PSA) expressed in L. tarentolae system (LEXSY, Jena Bio-
science), RAPSODI holds a promising future for a cross-protective
Leishmania vaccine.
Dendritic cell (DC) – based vaccines
DCs are a class of specialized APCs that orchestrate both innate
and acquired immunity. TLR:PAMP interaction leads to matu-
ration of DCs lying in the interface external environment and
mucosal surface, inducing the expression of co-stimulatory mole-
cules CD40, CD80, and CD86 required for T-cell activation. The
secreted cytokines, namely IFNs and IL-12 drive the T-cell differ-
entiation toward CD4+ Th1 or CD8+ CTL response. DC-based
anti-leishmanial vaccines comprise a novel yet nascent strategy for
long-lasting immunity (Moll and Berberich, 2001; Donaghy et al.,
2010). Generation of parasite-speciﬁc Th1 biased long-term pro-
tection by plasmacytoid DC-based vaccination against L. major
(Tsagozis et al., 2004; Remer et al., 2007) provided the thrust for
targeting DC vaccines againstVL. Adoptive transfer of DCs pulsed
ex vivo with soluble L. donovani Ags (SLDA) to naive mice induced
theAg-speciﬁc production of IFN-γ. However, complete clearance
of parasites from liver was attained only after IL-12-transduction
of SLDA-pulsed DCs (Ahuja et al., 1999). This outlines the impor-
tance of paracrine delivery of IL-12 for DC-based vaccination.
In a recent study, bone marrow-derived DCs (BM-DCs) pulsed
ex vivo with the peptide 12-31aa portion of kinetoplastid mem-
brane protein, KMP-11 (12-31aa) and CpG-ODN was protective
2http://www.fp7-rapsodi.eu/
in a murine model of VL (Agallou et al., 2011). In another study,
combination therapy using SLDA-pulsed syngenic bone marrow-
derived DC and antimony-based chemotherapy could cure estab-
lishedmurineVL viaCD4+ T cell dependent Th1 response (Ghosh
et al., 2003). Similar protective effects of microbial antigen-loaded
DCs have also been reported for other pathogens (Bourguin et al.,
1998; George-Chandy et al., 2001; McShane et al., 2002) and
antitumour immunity (Kobukai et al., 2011). Another interest-
ing approach has implemented hybrid cell vaccination therapy
using L. donovani kinetoplastid membrane protein-11 (KMP-
11)-transfected bone marrow-derived macrophages from BALB/c
mice with allogeneic bone marrow-derived DCs from C57BL/6
mice to resolve infection by establishing strong antigen-speciﬁc
CD8+ CTL response (Basu et al., 2007). DCs have been pro-
posed to play a critical role as immunomodulators in vaccination
and therapy, and are therefore an important tool for prophylactic
vaccination against serious infections. Integrating DC vaccina-
tions with standard anti-leishmanial chemotherapy could thus
be highly beneﬁcial for therapeutic vaccination against VL. Nev-
ertheless, this strategy has its limitations. Large-scale generation
of leishmanial Ag-pulsed and/or cytokine-transduced autologous
DC vaccine seems laborious and expensive, and could thus possi-
bly limit its use in developing countries. Moreover, the choice of
DC subtype, antigen-loading strategy, maturational status, route
and frequency of immunization, and adjuvant cytokines all affect
the performance of a DC vaccine.
THIRD GENERATION VACCINES
Genetic vaccination has been a better and ﬂexible strategic alter-
native for inducing stronger Th1 biased immune response than
their recombinant protein counterparts which often suffer from
poor immunogenicity due to alerted pathoantigenic epitopes
(Gurunathan et al., 1998; Rafati et al., 2006). An important feature
of DNA vaccination is the induction of CD8+ cytotoxic T cells
along with sufﬁcient CD4+ T cell and humoral response. This
contributes to cytolysis of parasite-infected cells by CD8+ T cells
and increased IFN-γ secretion for efﬁcient leishmanicidal activ-
ity (Aguilar-Be et al., 2005; Carter et al., 2007). However, priming
and expansion of CD8+ T cells solely depends upon CD4+ T cells
which is vital for initiation and maintenance of immune mem-
ory (Bourgeois et al., 2002; Janssen et al., 2003). This concept of
Th cell help for CTL response has led to further improvement
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of DNA vaccine constructs and adjuvant strategies over time. In
addition to codon-optimized vectors, fusion of immune modula-
tors (like CpG motifs, GM-CSF, Flt3 ligands, and cytokine genes)
and novel delivery systems like electroporation, and the concept
of heterologous prime-boosting have been employed successfully
against Leishmania and several other pathogens. gp63,Leishmania
analog of the receptor kinase C (LACK) and ORFF are the most
extensively studied DNA vaccine candidates against VL till date
(Table 2). Vaccination with a plasmid encoding LACK gene with
or without co-administration of 1L-12 resulted in robust, long-
lasting protection in mice against L. major (Gurunathan et al.,
1997, 1998; Stobie et al., 2000). Intranasal immunization with
plasmid carrying LACK has also been protective against L. cha-
gasi both in mice (Gomes et al., 2007) and hamster model (DE
Oliveira Gomes et al., 2011) of VL. In contrast to LACK, which
failed to protect against L. donovani (Melby et al., 2001b), prim-
ing with gp63 DNA with protein boost afforded robust, long-term
protection in susceptible BALB/c mice (Mazumder et al., 2011b).
Similarly, ORFF (Tewary et al., 2005), KMP-11 (Basu et al., 2005),
and cysteine proteases (Rafati et al., 2006) have been protective
as DNA vaccines against different Leishmania species. Protec-
tion was signiﬁcantly improved when vaccines were composed of
a cocktail of plasmids expressing immunodominant Leishmania
genes. Accordingly, vaccination of mice with cocktail of plasmids
harboring gp63 andHsp70 genes elicited robust protection against
L. donovani with enhanced IFN-γ and IL-2 driving toward an
excellentTh1biased immune response (Kaur et al., 2011a). Further
studies are required in higher animal models for such promising
combination vaccines to ensure protection before they are ﬁnally
evaluated in patients with VL. An interesting approach based on
cDNA libraries has been adopted to identify protective L. donovani
antigens through cDNA immunizations (Melby et al., 2000). Plas-
mid DNAs isolated from several cDNA sublibraries constructed
from amastigote-derived RNA have been screened by immuniza-
tionof BALB/cmice. Several groups of cDNAthat conferred in vivo
protection against subsequent L. donovani challenge have been
identiﬁed by this technique.
Several lines of evidence suggest a central role of DCs
in antigen presentation after DNA vaccination (Corr et al.,
1996; Akbari et al., 1999) which explains the success of DC-
targeted adjuvants like GM-CSF, TLRs, and Flt3 ligands when
co-administered with plasmid DNA (Encke et al., 2006). LEISHD-
NAVAX, based on MIDGE vector, developed by Mologen AG
(Berlin, Germany) is presently undergoing preclinical trials in
Europe, against visceral and cutaneous forms of leishmaniasis,
along with a double stem loop immunomodulator (DSLIM)
Table 2 |Third generation vaccine candidates for L. donovani.
Antigen Vaccine form/adjuvant used Animal model Challenge infection Result Reference
L. DONOVANI -DERIVEDANTIGENSTESTEDAGAINST L. DONOVANI
p36 LACK DNA vaccine+ IL-12 Mouse L. donovani No protection Melby et al. (2001b)
A2 DNA vaccine Mouse L. donovani Protection Ghosh et al. (2001a)
A2 Expressed in Lactococcus
lactis
Mouse L. donovani Protection Yam et al. (2011)
ORFF DNA vaccine Mouse L. donovani Partial protection Sukumaran et al. (2003)
ORFF-HPB DNA vaccine+ recombinant
protein
Mouse L. donovani Protection Tewary et al. (2005)
ORFF Ubiquitin conjugated DNA
vaccine
Mouse L. donovani Protection Sharma and Madhubala
(2009)
KMP-11 DNA vaccine Hamster L. donovani Protection Basu et al. (2005)
KMP-11 DNA vaccine+ IL-12 Mouse L. donovani, L. major Cross-protection Bhaumik et al. (2009)
γ GCS DNA vaccine Mouse L. donovani Protection Carter et al. (2007)
H2A,H2B, H3, H4, LACK Multiantigen DNA vaccine Dog L. donovani Partial protection Saldarriaga et al. (2006)
PPG-N-terminal domain DNA vaccine Hamster L. donovani Protection Samant et al. (2009)
gp63/polytope DNA vaccine/polytope/polytope
fused with hsp70
Mouse L. donovani Protection Sachdeva et al. (2009)
P1-HPB DNA vaccine+ recombinant
protein
Hamster L. donovani Protection Masih et al. (2011)
gp63-HPB DNA vaccine+ recombinant
protein+CpG-ODN
Mouse L. donovani, L. major Cross-protection Mazumder et al. (2011b)
L. DONOVANI -DERIVEDANTIGENSTESTEDAGAINST OTHER LEISHMANIA SPECIES
NH36 DNA vaccine Mouse L. chagasi, L. mexicana Cross-protection Aguilar-Be et al. (2005)
NH36 DNA vaccine Mouse L. chagasi Protection Gamboa-León et al. (2006)
A2 Expressed in adenovirus Mouse L. chagasi Protection Resende et al. (2008)
A2 Expressed in L. tarentolae Mouse L. infantum Protection Mizbani et al. (2009)
NH36, nucleoside hydrolase 36; HPB, heterologous prime-boost; KMP-11, kinetoplastid membrane protein-11; LACK, Leishmania analog of the receptors of activated
C kinase; PPG, proteophosphoglycan.
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adjuvant [Development of aDNAvaccine forVL: LEISHDNAVAX.
European Commission Research-Health;3 (accessed 2 January
2012)]. This multicomponent vaccine with three to four known
immunodominant leishmanial antigens holds a great therapeutic
and prophylactic potential against VL. Finally, safety issues must
be ensured during these early steps of DNA vaccine development
for human acceptance.
VL VACCINE DEVELOPMENT: NEW STRATEGIES
GENETICALLY ALTERED LIVE-ATTENUATED VACCINE
Vaccinationwith geneticallymodiﬁed Leishmania parasite is based
on decoupling virulence for induction of protective immunity.
This generally involves targeted disruption of virulence or essential
leishmanial genes resulting in mutated parasites lacking viru-
lence. These mutants closely mimic the natural course of infec-
tion through PAMPs required for adequate stimulation of innate
immunity for long-term immune memory. Such live-attenuated
vaccines have been successfully used against several viral and
bacterial pathogens (Nakhasi et al., 1989; Larsen et al., 2009).
Despite several attempts, very limited numbers of genetically
modiﬁed live-attenuated forms of L. donovani exist as vaccine can-
didates. Recently, L. donovani centrin null mutants (Ld Cen−/−)
have been reported to protect BALB/c mice and Syrian hamsters
against homologous as well as heterologous infectious challenge
(Selvapandiyan et al., 2009). Immune protection upon 10 week
post-virulent challenge correlated with Th1 biased response with
signiﬁcant increase in IFN-γ, IL-12, and TNF producing T cells
that signiﬁcantly lowered the parasite burden in spleen along
with complete clearance of parasites in liver. Similar Th1 biased
protection has been shown in mice immunized with L. dono-
vani biopterin transporter null mutant (BT1−/−) (Papadopoulou
et al., 2002) and silent information regulatory 2 single-knock out
mutants (Li SIR2±) of L. infantum against virulent challenge
(Silvestre et al., 2007). Similarly, cytochrome C oxidase com-
ponent p27 null mutants (Ld p27−/−) of L. donovani showed
less virulence both in human macrophages and in BALB/c mice
(Dey et al., 2010) which may be explored further. More recently,
a preliminary evaluation using L. infantum heat-shock protein
(HSP70-II) null mutant seems promising in inducing protection
in L. major-BALB/c infection model (Carrión et al., 2011).
An interestingly different approach using non-pathogenic
species like L. tarentolae as live vaccine showed enhanced anti-
gen presentation and potent Th1 response against L. donovani
challenge in BALB/c mice (Breton et al., 2005). Further reﬁne-
ment of this approach using recombinant L. tarentolae expressing
L. donovani A2 antigen was cross-protective against both L. infan-
tum (Mizbani et al., 2009, 2011) and L. donovani (Yam et al., 2011).
Overall, the use of live, non-pathogenic/genetically engineered
Leishmania seems to be the most promising strategic alternative
against VL. However, the underlying risk of reversion to viru-
lence chieﬂy in immunocompromised individuals is an important
limitation for their large-scale use.Additionally,presence of antibi-
otic resistant genes in attenuated parasite strains hinders their
use in clinical studies. Moreover, safety blocking of vaccine strain
3http://ec.europa.eu/research/health/infectious-diseases/neglected-diseases/
projects/006 en.html
transmissibility by sandﬂy vector is another important issue that
needs clariﬁcation.
PROTEOMIC APPROACHES
Proteomics, being widely applied in studying Leishmania spp., is a
powerful tool for elucidating bothmolecular pathology andmech-
anistic searching of novel vaccine targets often missed following
conventional techniques. Current immunoproteomics using two-
dimensional gel electrophoresis (2-DE) and matrix-assisted laser
desorption/ionizationmass spectrometry (MALDI-MS) approach
focuses on identiﬁcation and evaluation of responses to para-
site T-cell epitopes as putative vaccine targets. Recent proteome-
serological methodology using 2-D Western blot analyses from
clinical isolates and sera of Indian VL patients have led to detec-
tion of 330 different immunogenic antigens (Forgber et al., 2006).
Another systematic study detected a total of 33 T-cell stimulat-
ing antigens from soluble proteins of L. donovani clinical isolate,
M.W. ranging from 68 to 97.4 kDa (Gupta et al., 2007) that showed
signiﬁcant prophylactic potential against L. donovani challenge in
hamster model of VL (Garg et al., 2006). Availability of anno-
tated 32.8-Mb sequenced genomewith 8272 protein coding genes4
of L. major permits identiﬁcation of all potential protein prod-
ucts precisely outlining heterogeneity of complex host responses
to leishmanial antigenic variation, and will be useful in rational
designing of vaccine. Additional proteomic approaches analyzing
sandﬂy salivary components have identiﬁed a large prospective
candidate repertoire for vaccine development against leishmania-
sis (Titus and Ribeiro, 1988; Gillespie et al., 2000; Valenzuela et al.,
2004).
However, the ﬁeld of proteomics in Leishmania mostly lim-
its itself to cytosolic proteins thereby excluding many pathogenic
extracellular membrane proteins due to difﬁculties in solubilizing
their hydrophobic transmembrane domains. Also, the approach
remains insufﬁcient for identiﬁcation of protein subsets actually
being expressed in parasites. Combining biological functions of
identiﬁed proteins via activity-based techniques would accelerate
this process of post-genomic vaccine research in future.
SUBTRACTIVE GENOMICS
A very recently adopted methodology is based on subtraction
of sequence between host and parasite proteome. Availability of
whole genome sequence for human and pathogenic microbes has
been utilized to ﬁnd non-human homologous vaccine and ther-
apeutic targets against Helicobacter pylori (Huynen et al., 1998;
Dutta et al., 2006), Pseudomonas aeruginosa (Sakharkar et al.,
2004; Perumal et al., 2007), Mycobacterium pneumonia (Gupta
et al., 2010), Borrelia burgdorferi (Madagi et al., 2011), Chlamy-
dia trachomatis (Praveena et al., 2011) as well as L. donovani
(Mandage and Wadnerkar, 2010) that are currently facing the
problems of drug resistance or absence of vaccines. Thus sorted
key pathogenic proteins essential for parasite survival but non-
homologous to human host, are subsequently checked for their
cellular localization within the pathogen, exo-membrane topol-
ogy and role in metabolic pathways to be used for drug or
4http//www. genedb.org/leish/index.jsp
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prophylactic targets. Usually, conserved secreted and membrane
proteins from pathogens are selected to design novel vaccines
(Dutta et al., 2006; Barh et al., 2010). A preliminary work based on
computational subtractive genomics has identiﬁed protein kinase,
adenylate kinase and MAP kinase homolog of L. donovani for
regulating normal cell cycle and differentiation of the parasite
(Mandage and Wadnerkar, 2010). The experimental evaluation
of such vaccine targets is required to validate their prophylactic
potential. Further prediction of functional sites and exploration
of Leishmania proteome are required to get the full beneﬁt of
this approach for a cross-protective VL vaccine. Moreover, it is
advisable to consider all the pathogenic strains undertaking in sil-
ico mutagenesis approach and pangenomics data base, for further
improvement of this basic strategy.
CHALLENGES AND FUTURE PROSPECT
A major challenge in vaccination against Leishmania and several
other intracellular pathogens is the requirement of strong cell-
mediated immune response in mediating protection. Most of the
licensed prophylactic vaccines for human use rely completely on
humoral response which have limited efﬁcacy against Leishma-
nia. Although adjuvants like alum, AS04 (composed of MPLA
adsorbed to alum), MF59 and AS03 (oil-in-water emulsion) are
approved for human use, inability to trigger robust T-cell response
remains a potential short-coming of killed/subunit vaccines. None
of the Leishmania vaccines reaching clinical trials could show ade-
quate efﬁcacy due to poor CD8+ T-cell responses arising from
inefﬁcient cross-presentation. Live-attenuated vaccines are advan-
tageous in generating durable cellular (both CD4+ and CD8+)
response mostly due to temporary parasite persistence and proper
antigen presentation. However, they are largely precluded due to
safety reasons. Although, in the current scenario, a plasmid DNA
vaccine following heterologous prime-boost strategy seems to be
a promising prophylactic choice for generating robust cellular and
humoral response, they are largely tempered by chances of chronic
inﬂammation, autoantibody generation and systemic lupus ery-
thematosus (SLE), or integration into host genome thatmay either
activate oncogenes or deactivate tumor suppressor genes. Further,
optimization in terms of magnitude of T-cell response and safety
is warranted for genetic vaccinations before human administra-
tion. Additionally, most of the commonly used immunological
assays for evaluating adaptive immunity in vaccinated animals are
often insufﬁcient and need to be revitalized. Adoption of newer
sophisticated technologies like multiparametric ﬂow cytometry
for evaluating magnitude and quality of multifunctional T cells
simultaneously producing IFN-γ, IL-2, IL-10, and TNF-α can be
acquired for better correlation with diverse immunopathogen-
esis and protection (Selvapandiyan et al., 2009; Macedo et al.,
2012). Similarly, parasite quantiﬁcation in challenged animals by
real-time PCR can help quantify as little as 0.1 parasites thereby
improving the accuracy of detection compared to conventional
microscopic counting of organ smear impressions and limiting
dilution assay (Nicolas et al., 2002).
Today’s Leishmania vaccine research is focused upon bridging
the common cellular and molecular components of different but
interdependent systems of innate and adaptive immunity by cer-
tain immunomodulators to raise highly integrated defense against
the parasites. Although all new vaccine approaches may not suc-
ceed in inducing sustained life-long immunity againstVL, a short-
termTh1 biased responsemay also be appreciated for its therapeu-
tic prospects. Interestingly, cationic liposomes alone can stimulate
DCs with upregulation of CD80 and CD86 co-stimulatory mol-
ecules to generate humoral as well as CD4+ and CD8+ T-cell
response resulting in activation of MHC-II and MHC-I path-
ways for antigen presentation. Formulating these cationic vesi-
cles with lipid -based TLR ligands like MPL, imiquimods, etc.
can be safe, immensely potent adjuvants against VL, for stronger
combined CTL and antibody response. Moreover, the immuno-
logical paradigm governing natural resistance to L. donovani in
certain individuals from Indian endemic pockets of VL remains
unexplored, which can be immensely informative for vaccine
design. In conclusion, correct orientations of innate biology and
adjuvant research ﬁne tuned with emerging ﬁelds of immuno-
proteomics, Leishmania genome mining and system biology can
lead to absolute prophylactic anti-leishmanial vaccine in the near
future.
ACKNOWLEDGMENTS
This work was supported by grants from the Council of Scientiﬁc
and Industrial Research and the Department of Science and Tech-
nology, Government of India. We thank Sarfaraz Ahmad Ejazi for
his assistance during preparation of the manuscript.
REFERENCES
Abdelhak, S., Louzir, H., Timm, J.,
Blel, L., Benlasfar, Z., Lagranderie,
M., Gheorghiu, M., Dellagi, K., and
Gicquel, B. (1995). Recombinant
BCG expressing the leishmania sur-
face antigenGp63 induces protective
immunity against Leishmania major
infection in BALB/c mice. Microbi-
ology 141, 1585–1592.
Addy, M., and Nandy, A. (1992). Ten
years of kala-azar in west Bengal,
Part I. Did post-kala-azar dermal
leishmaniasis initiate the outbreak
in 24-Parganas? Bull. World Health
Organ. 70, 341–346.
Afrin, F., and Ali, N. (1997). Adju-
vanticity and protective immunity
elicited by Leishmania donovani
antigens encapsulated in positively
charged liposomes. Infect. Immun.
65, 2371–2377.
Afrin, F., Anam, K., and Ali, N.
(2000). Induction of partial protec-
tion against Leishmania donovani by
promastigote antigens in negatively
charged liposomes. J. Parasitol. 86,
730–735.
Afrin, F., Rajesh, R., Anam, K.,
Gopinath, M., Pal, S., and Ali,
N. (2002). Characterization of
Leishmania donovani antigens
encapsulated in liposomes that
induce protective immunity in
BALB/c mice. Infect. Immun. 70,
6697–6706.
Agallou, M., Margaroni, M., and
Karagouni, E. (2011). Cellular vac-
cination with bone marrow-derived
dendritic cells pulsed with a peptide
of Leishmania infantum KMP-11
and CpG oligonucleotides induces
protection in a murine model of
visceral leishmaniasis. Vaccine 29,
5053–5064.
Aguilar-Be, I., da Silva Zardo, R.,
Paraguai de Souza, E., Borja-
Cabrera, G. P., Rosado-Vallado,
M., Mut-Martin, M., García-Miss
Mdel, R., Palatnik de Sousa, C.
B., and Dumonteil, E. (2005).
Cross-protective efﬁcacy of a pro-
phylactic Leishmania donovani
DNA vaccine against visceral and
cutaneous murine leishmaniasis.
Infect. Immun.73, 812–819.
Ahuja, S. S., Reddick, R. L., Sato, N.,
Montalbo, E., Kostecki, V., Zhao,
W., Dolan, M. J., Melby, P. C.,
and Ahuja, S. K. (1999). Den-
dritic cell (DC)-based anti-infective
strategies: DCs engineered to secrete
IL-12 are a potent vaccine in
a murine model of an intracel-
lular infection. J. Immunol. 163,
3890–3897.
Akbari, O., Panjwani, N., Garcia, S., Tas-
con, R., Lowrie, D., and Stockinger,
B. (1999). DNA vaccination: trans-
fection and activation of dendritic
cells as key events for immunity. J.
Exp. Med. 189, 169–178.
www.frontiersin.org May 2012 | Volume 3 | Article 99 | 11
Das and Ali Vaccination against visceral leishmaniasis
Akuffo, H., Maasho, K., and Howe, R.
(1993). Natural and acquired resis-
tance to Leishmania: cellular acti-
vation by Leishmania aethiopica of
mononuclear cells from unexposed
individuals is through the stimula-
tion of natural killer (NK) cells.Clin.
Exp. Immunol. 94, 516–521.
Alexander, J., Carter, K. C., Al-Fasi,
N., Satoskar, A., and Brombacher,
F. (2000). Endogenous IL-4 is nec-
essary for effective drug therapy
against visceral leishmaniasis. Eur. J.
Immunol. 30, 2935–2943.
Ali, N., and Afrin, F. (1997). Protec-
tion of mice against visceral leish-
maniasis by immunizationwith pro-
mastigote antigen incorporated in
liposomes. J. Parasitol. 83, 70–75.
Alvar, J.,Yactayo, S., and Bern,C. (2006).
Leishmaniasis and poverty. Trends
Parasitol. 22, 552–557.
Anam,K.,Afrin, F., Banerjee,D., Prama-
nik, N., Guha, S. K., Goswami, R. P.,
Gupta, P. N., Saha, S. K., and Ali, N.
(1999a). Immunoglobulin subclass
distribution and diagnostic value of
Leishmania donovani antigen-speci-
ﬁc immunoglobulin G3 in Indian
kala-azar patients. Clin. Diagn. Lab.
Immunol. 6, 231–235.
Anam, K., Afrin, F., Banerjee, D., Pra-
manik, N., Guha, S. K., Goswami,
R. P., Saha, S. K., and Ali,
N. (1999b). Differential decline
in Leishmania membrane antigen-
speciﬁc immunoglobulin G (IgG),
IgM, IgE, and IgG subclass anti-
bodies in Indian kala-azar patients
after chemotherapy. Infect. Immun.
67, 6663–6669.
Anderson,C. F., Stumhofer, J. S.,Hunter,
C. A., and Sacks, D. (2009). IL-
27 regulates IL-10 and IL-17 from
CD4+ cells in nonhealing Leishma-
niamajor infection. J. Immunol. 183,
4619–4627.
Ansari, N. A., Kumar, R., Gautam,
S., Nylén, S., Singh, O. P., Sun-
dar, S., and Sacks, D. (2011). IL-
27 and IL-21 are associated with T
cell IL-10 responses in human vis-
ceral leishmaniasis. J. Immunol. 186,
3977–3985.
Armijos, R. X., Weigel, M. M., Hidalgo,
A., Cevallos, W., and Correa, J.
(2004). Safety, immunogenicity, and
efﬁcacy of an autoclaved Leishma-
nia amazonensis vaccine plus BCG
adjuvant against New World cuta-
neous leishmaniasis. Vaccine 22,
1320–1326.
Armitage, R. J., MacDuff, B. M., Eisen-
man, J., Paxton, R., and Grabstein,
K. H. (1995). IL-15 has stimulatory
activity for the induction of B cell
proliferation and differentiation. J.
Immunol. 154, 483–490.
Atta, A. M., D’Oliveira, C. J., Atta, M. L.,
Almeida, R. P., and Carvalho, E. M.
(1998). Anti-leishmanial IgE anti-
bodies: a marker of active disease in
visceral leishmaniasis. Am. J. Trop.
Med. Hyg. 59, 426–430.
Babaloo, Z., Kaye, P. M., and Eslami, M.
B. (2001). Interleukin-13 in Iranian
patients with visceral leishmaniasis:
relationship to other Th2 and Th1
cytokines. Trans. R. Soc. Trop. Med.
Hyg. 95, 85–88.
Bacellar, O., Brodskyn, C., Guerreiro, J.,
Barral-Netto, M., Costa, C. H., Coff-
man, R. L., Johnson,W. D., and Car-
valho, E. M. (1996). Interleukin-12
restores interferon-gamma produc-
tion and cytotoxic responses in vis-
ceral leishmaniasis. J. Infect. Dis. 173,
1515–1518.
Badaro, R., Falcoff, E., Badaro, F. S.,
Carvalho, E. M., Pedral-Sampaio,D.,
Barral, A., Carvalho, J. S., Barral-
Netto, M., Brandely, M., Silva, L.,
Bina, J. C., Teixeira, R., Falcoff, R.,
Rocha, H., Ho, J. L., and Johnson,
W. D. Jr. (1990). Treatment of vis-
ceral leishmaniasis with pentavalent
antimony and interferon gamma. N.
Engl. J. Med. 322, 16–21.
Badaro, R., and Johnson, W. D. Jr.
(1993). The role of interferon-
gamma in the treatment of visceral
and diffuse cutaneous leishmaniasis.
J. Infect. Dis. 167, 13–17.
Banchereau, J., and Steinman, R. M.
(1998). Dendritic cells and the
control of immunity. Nature 392,
245–252.
Barbier, D., Demenais, F., Lefait, J. F.,
David, B., Blanc, M., Hors, J., and
Feingold, N. (1987). Susceptibility
to human cutaneous leishmaniasis
and HLA, Gm, Km markers. Tissue
Antigens 30, 63–67.
Barh, D., Misra, A. N., and Kumar,
A. (2010). In silico identiﬁcation
of dual ability of N. gonorrhoeae
ddl for developing drug and vac-
cine against pathogenic Neisseria
and other human pathogens. J. Pro-
teomics Bioinform. 3, 082–090.
Barral-Netto, M., Barral, A., Brownell,
C. E., Skeiky, Y. A., Ellingsworth, L.
R., Twardzik, D. R., and Reed, S. G.
(1992). Transforming growth factor-
beta in leishmanial infection: a para-
site escape mechanism. Science 257,
545–548.
Basu, R., Bhaumik, S., Basu, J. M.,
Naskar,K.,De,T., and Roy, S. (2005).
Kinetoplastid membrane protein-11
DNA vaccination induces complete
protection against both pentava-
lent antimonial-sensitive and -
resistant strains of Leishmania dono-
vani that correlates with inducible
nitric oxide synthase activity and
IL-4 generation: evidence for mixed
Th1- and Th2-like responses in vis-
ceral leishmaniasis. J. Immunol. 174,
7160–7171.
Basu, R., Bhaumik, S., Haldar, A. K.,
Naskar, K., De, T., Dana, S. K.,
Walden, P., and Roy, S. (2007).
Hybrid cell vaccination resolves
Leishmania donovani infection by
eliciting a strong CD8+ cytotoxic T-
lymphocyte response with concomi-
tant suppression of interleukin-10
(IL-10) but not IL-4 or IL-13. Infect.
Immun. 75, 5956–5966.
Belkaid, Y., Mendez, S., Lira, R.,
Kadambi, N., Milon, G., and Sacks,
D. (2000). A natural model of Leish-
mania major infection reveals a
prolonged “silent” phase of par-
asite ampliﬁcation in the skin
before the onset of lesion forma-
tion and immunity. J. Immunol. 165,
969–977.
Beverley, S. M., and Turco, S. J. (1998).
Lipophosphoglycan (LPG) and the
identiﬁcation of virulence genes in
the protozoan parasite Leishmania.
Trends Microbiol. 6, 35–40.
Bhardwaj, S., Vasishta, R. K., and Arora,
S. K. (2009). Vaccination with a
novel recombinant Leishmania anti-
gen plus MPL provides partial pro-
tection against L. donovani chal-
lenge in experimental model of vis-
ceral leishmaniasis. Exp. Parasitol.
121, 29–37.
Bhaumik, S., Basu, R., Sen, S., Naskar,
K., and Roy, S. (2009). KMP-11DNA
immunization signiﬁcantly protects
against L. donovani infection but
requires exogenous IL-12 as an
adjuvant for comparable protec-
tion against L. major. Vaccine 27,
1306–1316.
Bhowmick, S., and Ali, N. (2009). Iden-
tiﬁcation of novel Leishmania dono-
vani antigens that help deﬁne cor-
relates of vaccine-mediated protec-
tion in visceral leishmaniasis. PLoS
ONE 4, e5820. doi:10.1371/jour-
nal.pone.0005820
Bhowmick, S., Mazumdar, T., and Ali,
N. (2009). Vaccination route that
induces transforming growth factor
beta production fails to elicit pro-
tective immunity against Leishmania
donovani infection. Infect. Immun.
77, 1514–1523.
Bhowmick, S., Mazumdar, T., Sinha, R.,
and Ali, N. (2010). Comparison of
liposome based antigen delivery sys-
tems for protection against Leishma-
nia donovani. J. Control Release 141,
199–207.
Bhowmick, S.,Ravindran,R., andAli,N.
(2007). Leishmanial antigens in lipo-
somes promote protective immu-
nity and provide immunotherapy
against visceral leishmaniasis via
polarized Th1 response. Vaccine 25,
6544–6556.
Bhowmick, S., Ravindran, R., and Ali,
N. (2008). gp63 in Stable cationic
liposomes confers sustained vaccine
immunity to susceptible BALB/c
mice infectedwith Leishmania dono-
vani. Infect. Immun. 76, 1003–1015.
Blackwell, J. M. (1996). Genetic sus-
ceptibility to leishmanial infections:
studies in mice and man. Parasitol-
ogy 112 (Suppl.), S67–S74.
Blackwell, J. M., Mohamed, H. S., and
Ibrahim, M. E. (2005). Genetics and
visceral leishmaniasis in the Sudan:
seeking a link. Trends Parasitol. 20,
268–274.
Bocarsly, P., Tomai, M. A., and Vasi-
lakos, J. P. (2002). Plasmacytoid den-
dritic cells produce cytokines and
mature in response to the TLR7 ago-
nists, imiquimod and resiquimod.
Cell. Immunol. 218, 74–86.
Bogdan, C., Gessner, A., Solbach, W.,
and Röllinghoff, M. (1996). Inva-
sion, control and persistence of
Leishmania parasites. Curr. Opin.
Immunol. 84, 517–525.
Bogdan, C., and Rollinghoff, M. (1998).
The immune response to Leishma-
nia: mechanisms of parasite con-
trol and evasion. Int. J. Parasitol. 28,
121–134.
Borja-Cabrera, G. P., Correia Pontes, N.
N., da Silva,V. O., Paraguai de Souza,
E., Santos, W. R., Gomes, E. M., Luz,
K. G., Palatnik, M., and Palatnik de
Sousa, C. B. (2002). Long lasting
protection against canine kala-azar
using the FML-QuilA saponin vac-
cine in an endemic area of Brazil
(São Gonçalo do Amarante, RN).
Vaccine 20, 3277–3284.
Bourgeois, C., Veiga-Fernandes, H.,
Joret, A. M., Rocha, B., and Tan-
chot, C. (2002). CD8 lethargy in
the absence of CD4 help. Eur. J.
Immunol. 32, 2199–2207.
Bourguin, I., Moser, M., Buzoni-Gatel,
D., Tielemans, F., Bout,D.,Urbain, J.,
andLeo,O. (1998).Murine dendritic
cells pulsed in vitro with Toxoplasma
gondii antigens induce protective
immunity in vivo. Infect. Immun. 66,
4867.
Bradley, D. J. (1974). Letter: genetic
control of natural resistance to
Leishmania donovani. Nature 250,
353–354.
Brandonisio, O., Spinelli, R., and Pepe,
M. (2004). Dendritic cells in Leish-
mania infection. Microbes Infect. 6,
1402–1409.
Bray, R. S. (1976). “Immunodiagno-
sis of leishmaniasis,” in Immunol-
ogy of Parasite Infection, eds S.
Cohen and E. H. Sadun (Oxford:
Frontiers in Immunology | Microbial Immunology May 2012 | Volume 3 | Article 99 | 12
Das and Ali Vaccination against visceral leishmaniasis
Blackwell Scientiﬁc Publications),
65–66.
Breton, M., Tremblay, M. J., Ouellette,
M., and Papadopoulou, B. (2005).
Live nonpathogenic parasitic vector
as a candidate vaccine against vis-
ceral leishmaniasis. Infect. Immun.
73, 6372–6782.
Bruhn, K. W., Birnbaum, R., Haskell,
J., Vanchinathan, V., Greger, S.,
Narayan, R., Chang, P. L., Tran, T.
A., Hickerson, S. M., Beverley, S. M.,
Wilson, M. E., and Craft, N. (2012).
Killed butmetabolically active Leish-
mania infantum as a novel whole-
cell vaccine for visceral leishma-
niasis. Clin. Vaccine Immunol. 19,
490–498.
Buates, S., and Matlashewski, G. (1999).
Treatment of experimental leishma-
niasis with the immunomodulators
imiquimod and S-28463: efﬁcacy
and mode of action. J. Infect. Dis.
179, 1485–1494.
Bucheton, B., Abel, L., Kheir, M. M.,
Mirgani,A.,El-Saﬁ,S.H.,Chevillard,
C., and Dessein, A. (2003). Genetic
control of visceral leishmaniasis in
a Sudanese population: candidate
gene testing indicates a linkage to the
NRAMP1 region. Genes Immun. 4,
104–109.
Bucheton, B., Kheir, M. M., El-Saﬁ, S.
H., Hammad, A., Mergani, A., Mary,
C., Abel, L., and Dessein, A. (2002).
The interplay between environmen-
tal and host factors during an out-
break of visceral leishmaniasis in
eastern Sudan. Microbes Infect. 14,
1449–1457.
Caldas, A., Favali, C., Aquino, D., Vin-
has, V., van Weyenbergh, J., Brod-
skyn, C., Costa, J., Barral-Netto, M.,
and Barral, A. (2005). Balance of
IL-10 and interferon-gamma plasma
levels in human visceral leishma-
niasis: implications in the patho-
genesis. BMC Infect. Dis. 5, 113.
doi:10.1186/1471-2334-5-113
Carrión, J., Folgueira, C., Soto, M.,
Fresno, M., and Requena, J. M.
(2011). Leishmania infantum
HSP70-II null mutant as candidate
vaccine against leishmaniasis: a
preliminary evaluation. Parasit.
Vectors 4, 150.
Carrión, J., Nieto, A., Iborra, S., Iniesta,
V., Soto,M., Folgueira, C., Abanades,
D. R., Requena, J. M., and Alonso,
C. (2006). Immunohistological fea-
tures of visceral leishmaniasis in
BALB/c mice. Parasite Immunol. 28,
173–183.
Carson, W. E., Giri, J. G., Lindermann,
M. J., Linett, M. L., Ahdieh, M., Pax-
ton, R., Anderson, D., Eisenmann,
J., Grabstein, K., and Caligiuri, M.
A. (1994). Interleukin-(IL)-15 is a
novel cytokine that activates human
natural killer cells via components of
the IL-2 receptor. J. Exp. Med. 180,
1395–1403.
Carson, W. E., Ross, M. E., Baiocchi,
R. A., Marien, M. J., Boiani, N.,
Grabstein, K., and Caligiuri, M. A.
(1995). Endogenous production of
interleukin-15 by activated human
monocytes is critical for optimal
production of interferon-gamma by
natural killer cells in vitro. J. Clin.
Invest. 96, 2578–2582.
Carter, K. C., Henriquez, F. L., Camp-
bell, S. A., Roberts, C. W., Nok,
A., Mullen, A. B., and McFar-
lane, E. (2007). DNA vaccina-
tion against the parasite enzyme
gamma glutamylcysteinesynthetase
confers protection against Leishma-
nia donovani infection. Vaccine 25,
4502–4509.
Carvalho, E. M., Bacellar, O., Brownell,
C., Regis, T., Coffman, R. L.,
and Reed, S. G. (1994). Restora-
tion of IFN-gamma production and
lymphocyte proliferation in vis-
ceral leishmaniasis. J. Immunol. 152,
5949–5956.
Chakravarty, J., Kumar, S., Trivedi, S.,
Rai, V. K., Singh, A., Ashman, J. A.,
Laughlin, E. M., Coler, R. N., Kahn,
S. J., Beckmann, A. M., Cowgill, K.
D.,Reed,S.G.,Sundar,S., andPiazza,
F. M. (2011). A clinical trial to eval-
uate the safety and immunogenic-
ity of the LEISH-F1+MPL-SE vac-
cine for use in the prevention of
visceral leishmaniasis. Vaccine 29,
3531–3537.
Chappuis, F., Sundar, S., Hailu, A.,
Ghalib, H., Rijal, S., Peeling, R. W.,
Alvar, J., and Boelaert, M. (2007).
Visceral leishmaniasis: what are the
needs for diagnosis, treatment and
control? Nat. Rev. Microbiol. 5,
873–882.
Chenik, M., Louzir, H., Ksontini, H.,
Dilou, A., Abdmouleh, I., and Del-
lagi, K. (2006). Vaccination with
the divergent portion of the pro-
tein histone H2B of Leishma-
nia protects susceptible BALB/c
mice against a virulent challenge
with Leishmania major. Vaccine 24,
2521–2529.
Clarêncio, J., de Oliveira, C. I., Favali,
C., Medina, O., Caldas, A., Costa,
C. H., Costa, D. L., Brodskyn, C.,
Barral, A., and Barral-Netto, M.
(2009). Could the lower frequency of
CD8+CD18+CD45RO+ lympho-
cytes be biomarkers of human VL?
Int. Immunol. 212, 137–144.
Coler, R. N., Yasuyuki, G., Bogatzki, L.,
Raman, V., and Reed, S. G. (2007).
Leish-111f, a recombinant polypro-
tein vaccine that protects against
visceral leishmaniasis by elicitation
of CD4 T cells. Infect. Immun. 75,
4648–4654.
Corr, M., Lee, D. J., Carson, D. A., and
Tighe, H. (1996). Gene vaccination
with naked plasmid DNA: mecha-
nism of CTL priming. J. Exp. Med.
184, 1555–1560.
da Matta, V. L., Hoshino-Shimizu,
S., Dietze, R., and Corbett, C. E.
(2000). Detection of speciﬁc anti-
body isotypes and subtypes before
and after treatment of American vis-
ceral leishmaniasis. J. Clin. Lab.Anal.
14, 5–12.
Davies, C. R., and Mazloumi Gavgani,
A. S. (1999). Age, acquired immu-
nity and the risk of visceral leishma-
niasis: a prospective study in Iran.
Parasitology 119, 247–257.
DE Oliveira Gomes, D. C., DA Silva
Costa Souza, B. L., DE Matos
Guedes, H. L., Lopes, U. G.,
and Rossi-Bergmann, B. (2011).
Intranasal immunization with
LACK-DNA promotes protective
immunity in hamsters chal-
lenged with Leishmania chagasi.
Parasitology 138, 1892–1897.
Demant, P., Lipoldova, M., and Svo-
bodova, M. (1996). Resistance to
Leishmania major in mice. Science
274, 1392–1393.
Dereure, J., El-Saﬁ, S. H., Bucheton, B,
Boni, M., Kheir, M. M., Davoust,
B., Pratlong, F., Feugier, E., Lam-
bert, M., Dessein, A., and Dedet,
J. P. (2003). Visceral leishmania-
sis in eastern Sudan: parasite iden-
tiﬁcation in humans and dogs;
host-parasite relationships.Microbes
Infect. 5, 1103–1108.
Desjardins, M., and Descoteaux, A.
(1997). Inhibition of phagolysoso-
mal biogenesis by the Leishmania
lipophosphoglycan. J. Exp.Med. 185,
2061–2068.
Dey, R., Meneses, C., Salotra, P.,
Kamhawi, S., Nakhasi, H. L., and
Duncan, R. (2010). Characteri-
zation of a Leishmania stage-
speciﬁc mitochondrial membrane
protein that enhances the activity
of cytochrome c oxidase and its
role in virulence. Mol. Microbiol. 77,
399–414.
Dole, V. S., Raj, V. S., Ghosh, A., Mad-
hubala, R., Myler, P. J., and Stuart,
K. D. (2000). Immunization with
recombinant LD1 antigens protects
against experimental leishmaniasis.
Vaccine 19, 423–430.
D’Oliveira Júnior, A., Costa, S. R., Bar-
bosa, A. B., Orge M de la, G., and
Carvalho, E. M. (1997). Asymp-
tomatic Leishmania chagasi infec-
tion in relatives and neighbors of
patients with visceral leishmaniasis.
Mem. Inst. Oswaldo Cruz 92,
15–20.
Dominguez, M., Moreno, I., Lopez-
Trascasa, M., and Torano, A. (2002).
Complement interaction with try-
panosomatid promastigotes in nor-
mal human serum. J. Exp. Med. 195,
451–459.
Donaghy, L., Cabillic, F., Corlu, A.,
Rostan, O., Toutirais, O., Guguen-
Guillouzo, C., Guiguen, C., and
Gangneux, J. P. (2010). Immunos-
timulatory properties of dendritic
cells after Leishmania donovani
infection using an in vitro model of
liver microenvironment. PLoS Negl.
Trop. Dis. 4, e703. doi:10.1371/jour-
nal.pntd.0000703
Dube, A., Sharma, P., Srivastava,
J. K., Misra, A., Naik, S., and
Katiyar, J. C. (1998). Vaccina-
tion of langur monkeys (Pres-
bytis entellus) against Leishmania
donovani with autoclaved L. major
plus BCG. Parasitology 116(Pt 3),
219–221.
Dutta, A., Singh, S. K., Ghosh, P.,
Mukherjee,R.,Mitter, S., andBandy-
opadhyay, D. (2006). In silico iden-
tiﬁcation of potential therapeutic
targets in the human pathogen
Helicobacter pylori. In silico Biol.
(Gedrukt) 6, 43–47.
Encke, J., Bernardin, J., Geib, J., Bar-
bakadze, G., Bujdoso, R., and Strem-
mel, W. (2006). Genetic vaccina-
tion with Flt3-L and GM-CSF as
adjuvants: enhancement of cellular
andhumoral immune responses that
results in protective immunity in a
murine model of hepatitis c virus
infection. World J. Gastroenterol. 12,
7118–7125.
Engwerda, C. R., Ato, M., and Kaye, P.
M. (2004). Macrophages, pathology
and parasite persistence in experi-
mental visceral leishmaniasis.Trends
Parasitol. 20, 524–530.
Fakiola, M., Miller, E. N., Fadl, M.,
Mohamed, H. S., Jamieson, S. E.,
Francis, R. W., Cordell, H. J., Pea-
cock, C. S., Raju, M., Khalil, E. A.,
Elhassan, A., Musa, A. M., Silveira,
F., Shaw, J. J., Sundar, S., Jeronimo,
S. M., Ibrahim, M. E., and Black-
well, J. M. (2011). Genetic and func-
tional evidence implicating DLL1 as
the gene that inﬂuences susceptibil-
ity to visceral leishmaniasis at chro-
mosome 6q27. J. Infect. Dis. 204,
467–477.
Favali, C., Tavares, N., Clarêncio, J., Bar-
ral, A., Barral-Netto, M., and Brod-
skyn, C. (2007). Leishmania ama-
zonensis infection impairs differ-
entiation and function of human
dendritic cells. J. Leukoc. Biol. 82,
1401–1406.
www.frontiersin.org May 2012 | Volume 3 | Article 99 | 13
Das and Ali Vaccination against visceral leishmaniasis
Forgber, M., Basu, R., Roychoudhury,
K., Theinert, S., Roy, S., Sundar, S.,
and Walden, P. (2006). Mapping the
antigenicity of the parasites in Leish-
mania donovani infection by pro-
teome serology. PLoS ONE 1, e40.
doi:10.1371/journal.pone.0000040
Gamboa-León, R., Paraguai de Souza,
E., Borja-Cabrera, G. P., Santos, F.
N., Myashiro, L. M., Pinheiro, R.
O., Dumonteil, E., and Palatnik-de-
Sousa,C. B. (2006). Immunotherapy
against visceral leishmaniasis with
the nucleoside hydrolase-DNA vac-
cine of Leishmania donovani.Vaccine
24, 4863–4873.
Gantt, K. R., Schultz-Cherry, S.,
Rodriguez, N., Jeronimo, S. M.,
Nascimento, E. T., Goldman, T.
L., Recker, T. J., Miller, M. A., and
Wilson, M. E. (2003). Activation of
TGF beta by Leishmania chagasi:
importance for parasite survival
in macrophages. J. Immunol. 170,
2613–2620.
Garg, R., Gupta, S. K., Tripathi, P.,
Hajela, K., Sundar, S., Naik, S.,
and Dube, A. (2006). Leishmania
donovani: identiﬁcation of stimula-
tory soluble antigenic proteins using
cured human, and hamster lympho-
cytes for their prophylactic poten-
tial against visceral leishmaniasis.
Vaccine 24, 2900–2909.
Genaro, O., de Toledo, V. P., da Costa,
C. A., Hermeto, M. V., Afonso, L. C.,
and Mayrink,W. (1996). Vaccine for
prophylaxis and immunotherapy,
Brazil. Clin. Dermatol. 14, 503–512.
George-Chandy, A., Mielcarek, N.,
Nordström, I., Holmgren, J., and
Eriksson, K. (2001). Vaccination
with Bordetella pertussis-pulsed
autologous or heterologous den-
dritic cells induces a mucosal
antibody response in vivo and
protects against infection. Infect.
Immun. 69, 4120–4124.
Ghalib, H. W., Piuvezam, M. R., Skeiky,
Y. A., Siddig, M., Hashim, F. A., el-
Hassan, A. M., Russo, D. M., and
Reed, S. G. (1993). Interleukin 10
production correlates with pathol-
ogy in human Leishmania dono-
vani infections. J. Clin. Invest. 92,
324–329.
Ghalib, H. W., Whittle, J. A., Kubin,
M., Hashim, F. A., el-Hassan, A.
M., Grabstein, K. H., Trinchieri,
G., and Reed, S. G. (1995). IL-
12 enhances Th1-type responses in
human Leishmania donovani infec-
tions. J. Immunol. 154, 4623–4629.
Ghosh, A., Labrecque, S., and Mat-
lashewski, G. (2001a). Protection
against Leishmania donovani infec-
tion by DNA vaccination: increased
DNA vaccination efﬁciency through
inhibiting the cellular p53 response.
Vaccine 19, 3169–3178.
Ghosh, A., Zhang, W. W., and
Matlashewski, G. (2001b). Immu-
nization with A2 protein results in
a mixed Th1/Th2 and a humoral
response which protects mice
against Leishmania donovani
infections. Vaccine 20, 59–66.
Ghosh, M., Pal, C., Ray, M., Maitra,
S., Mandal, L., and Bandyopad-
hyay, S. (2003). Dendritic cell-
based immunotherapy combined
with antimony-based chemother-
apy cures established murine vis-
ceral leishmaniasis. J. Immunol. 170,
5625–5629.
Gibson, S. J., Lindh, J. M., Riter, T. R.,
Gleason, R. M., Rogers, L. M., Fuller,
A. E., Oesterich, J. L., Gorden, K. B.,
Qiu, X., McKane, S. W., Noelle, R. J.,
Miller, R. L., Kedl, R. M., Fitzgerald-
Bocarsly, P., Tomai, M. A., and Vasi-
lakos, J. P. (2002). Plasmacytoid den-
dritic cells produce cytokines and
mature in response to the TLR7 ago-
nists, imiquimod and resiquimod.
Cell. Immunol. 218, 74–86.
Gillespie, R. D., Mbow, M. L., and Titus,
R. G. (2000). The immunomodula-
tory factors of blood feeding arthro-
pod saliva. Parasite Immunol. 22,
319–331.
Gomes, N. A., Gattass, C. R., Barreto-
De-Souza, V., Wilson, M. E.,
and DosReis, G. A. (2000).
TGF-beta mediates CTLA-4
suppression of cellular immunity in
murine kalaazar. J. Immunol. 164,
2001–2008.
Gomes, D. C., Pinto, E. F., de Melo, L.
D., Lima,W. P., Larraga,V., Lopes, U.
G., and Rossi-Bergmann, B. (2007).
Intranasal delivery of naked DNA
encoding the LACK antigen leads to
protective immunity against visceral
leishmaniasis in mice. Vaccine 25,
2168–2172.
Gomes, R., Teixeira, C., Teixeira, M. J.,
Oliveira, F., Menezes, M. J., Silva,
C., de Oliveira, C. I., Miranda, J. C.,
Elnaiem, D. E., Kamhawi, S., Valen-
zuela, J. G., and Brodskyn, C. I.
(2008). Immunity to a salivary pro-
tein of a sand ﬂy vector protects
against the fatal outcome of visceral
leishmaniasis in a hamster model.
Proc. Natl. Acad. Sci. U.S.A. 105,
7845–7850.
Gradoni, L. (2001). An update on
antileishmanial vaccine candidates
and prospects for a canine Leish-
mania vaccine. Vet. Parasitol. 100,
87–103.
Green, S. J., Meltzer, M. S., Hibbs, J. B.
Jr., and Nacy, C. A. (1990). Activated
macrophages destroy intracellular
Leishmania major amastigotes by an
L-arginine-dependent killing mech-
anism. J. Immunol. 144, 278–283.
Gueirard, P., Laplante, A., Rondeau,
C., Milon, G., and Desjardins, M.
(2008). Trafﬁcking of Leishmania
donovani promastigotes in non-
lytic compartments in neutrophils
enables the subsequent transfer
of parasites to macrophages. Cell.
Microbiol. 10, 100–111.
Gupta, S. K., Singh, S., Gupta, M.
K., Pant, K. K., and Seth, P.
K. (2010). Identiﬁcation of poten-
tial targets in Mycoplasma pneu-
monia through subtractive genome
analysis. J. Antivir. Antiretrovir. 2,
038–041.
Gupta, S. K., Sisodia, B. S., Sinha,
S., Hajela, K., Naik, S., Shasany,
A. K., and Dube, A. (2007). Pro-
teomic approach for identiﬁca-
tion and characterization of novel
immunostimulatory proteins from
soluble antigens of Leishmania dono-
vani promastigotes. Proteomics 7,
816–823.
Gurunathan, S., Prussin, C., Sacks, D.
L., and Seder, R. A. (1998). Vac-
cine requirements for sustained cel-
lular immunity to an intracellu-
lar parasitic infection. Nat. Med. 4,
1409–1415.
Gurunathan, S., Sacks, D. L., Brown,
D. R., Reiner, S. L., Charest, H.,
Glaichenhaus, N., and Seder, R.
A.(1997). Vaccination with DNA
encoding the immunodominant
LACK parasite antigen confers pro-
tective immunity to mice infected
with Leishmania major. J. Exp. Med.
186, 1137–1147.
Hailu, A., Menon, J. N., Berhe, N.,
Gedamu, L., Hassard, T. H., Kager,
P. A., Olobo, J., and Bretscher, P.
A. (2001). Distinct immunity in
patients with visceral leishmaniasis
from that in subclinically infected
and drug-cured people: implications
for the mechanism underlying drug
cure. J. Infect. Dis. 184, 112–115.
Handman, E. (2001). Leishmaniasis:
current status of vaccine devel-
opment. Clin. Microbiol. Rev. 14,
229–243.
Handman,E.,Button,L. L., andMcMas-
ter, R. W. (1990). Leishmania major :
production of recombinant gp63,
its antigenicity and immunogenic-
ity in mice. Exp. Parasitol. 70,
427–435.
Handman, E. and Mitchell G. F.
(1985). Immunization with Leish-
mania receptor for macrophages
protects mice against cutaneous
leishmaniasis. Proc. Natl. Acad. Sci.
U.S.A. 82, 5910–5914.
Harms, G., Zwingenberger, K., Sand-
kamp, B., Omena, S., Pedrosa, C.,
Richter, J., Rosenkaimer, F., Feld-
meier, H., and Bienzle, U. (1993).
Immunochemotherapy of visceral
leishmaniasis: a pilot trial of sequen-
tial treatment with recombinant
interferon-gamma and pentavalent
antimony. J. Interferon Res. 13,
39–41.
Hayashi, F., Means, T. K., and Luster, A.
D. (2003). Toll-like receptors stim-
ulate human neutrophil function.
Blood 10, 2660–2669.
Hemmi, H., Kaisho, T., Takeuchi, O.,
Sato,S., Sanjo,H.,Hoshino,K.,Hori-
uchi, T., Tomizawa, H., Takeda, K.,
andAkira, S. (2002). Small anti-viral
compounds activate immune cells
via the TLR7MyD88-dependent sig-
naling pathway. Nat. Immunol. 3,
196–200.
Henriquez, F. L., Campbell, S. A.,
Roberts, C. W., Mullen, A. B.,
Burchmore, R., and Carter, K. C.
(2010). Vaccination with recombi-
nant Leishmania donovani gamma-
glutamylcysteine synthetase fusion
protein protects against L. donovani
infection. J. Parasitol. 96, 929–936.
Hotez, P. J., Remme, H. F., Buss, P.,
George,G.,Morel,C., and Breman, J.
G. (2004). Combating tropical infec-
tious diseases: report of the dis-
ease control priorities in developing
countries project. Clin. Infect. Dis.
38, 871–878.
Huynen, M., Dandekar, T., and Bork, P.
(1998). Differential genome analysis
applied to the species-speciﬁc fea-
tures of Helicobacter pylori. FEBS
Lett. 426, 1–5.
Iborra, S., Carrión, J., Anderson, C.,
Alonso, C., Sacks, D., and Soto, M.
(2005). Vaccination with the Leish-
mania infantum acidic ribosomal
P0 protein plus CpG oligodeoxynu-
cleotides induces protection against
cutaneous leishmaniasis in C57BL/6
mice but does not prevent progres-
sive disease in BALB/c mice. Infect.
Immun. 73, 5842–5852.
Ilg, T. (2000). Lipophosphoglycan
is not required for infection of
macrophages or mice by Leishmania
mexicana. EMBO J. 19, 1953–1962.
Jaafari, M. R., Badiee, A., Khamesipour,
A., Samiei, A., Soroush, D., Kheiri,
M. T., Barkhordari, F., McMaster,W.
R., and Mahboudi, F. (2007) The
role of CpG ODN in enhancement
of immune response and protec-
tion in BALB/c mice immunized
with recombinant major surface gly-
coprotein of Leishmania (rgp63)
encapsulated in cationic liposome.
Vaccine 25, 6107–6117.
Jaafari, M. R., Ghafarian, A., Farrokh-
Gisour, A., Samiei, A., Kheiri, M.
T., Mahboudi, F., Barkhordari, F.,
Frontiers in Immunology | Microbial Immunology May 2012 | Volume 3 | Article 99 | 14
Das and Ali Vaccination against visceral leishmaniasis
Khamesipour, A., and McMaster,
W. R. (2006). Immune response
and protection assay of recombinant
major surface glycoprotein of Leish-
mania (rgp63) reconstituted with
liposomes in BALB/c mice. Vaccine
24, 5708–5717.
Jaffe,C. L.,Rachamim,N., and Sarfstein,
R. (1990). Characterization of two
proteins from Leishmania donovani
and their use for vaccination against
visceral leishmaniasis. J. Immunol.
144, 699–706.
Jain, M., and Madhubala, R. (2008).
Characterization and localization of
ORFF gene from the LD1 locus
of Leishmania donovani. Gene 416,
1–10.
Janssen, E. M., Lemmens, E. E., Wolfe,
T., Christen, U., von Herrath, M.
G., and Schoenberger, S. P. (2003).
CD4+ T cells are required for sec-
ondary expansion and memory in
CD8+ T lymphocytes. Nature 421,
852–856.
Jardim, A., Alexander, J., Teh, H. S.,
Ou, D. W., and Olafson, R. W.
(1990). Immunoprotective Leishma-
nia major synthetic T cell epitopes.
J. Exp. Med. 172, 645–648.
Joshi, T., Rodriguez, S., Perovic, V.,
Cockburn, I. A., and Stager, S.
(2009). B7-H1 blockade increases
survival of dysfunctional CD8+
T cells and confers protection
against Leishmania donovani infec-
tions. PLoS Pathog. 5, e1000431.
doi:10.1371/journal.ppat.1000431
Jullien, D., Sieling, P. A., Uyemura, K.,
Mar, N. D., Rea, T. H., and Modlin,
R. L. (1997). IL-15, an immunomod-
ulator of T cell responses in intra-
cellular infection. J. Immunol. 158,
800–806.
Kahl, L. P., Lelchuk, R., Scott, C. A.,
and Beesley, J. (1990). Characteriza-
tion of Leishmania major antigen-
liposomes that protect BALB/c
mice against cutaneous leishmania-
sis. Infect. Immun. 58, 3233–3241.
Kaisho, T., and Akira, S. (2000). Crit-
ical roles of Toll-like receptors in
host defense. Crit. Rev. Immunol. 20,
393–405.
Kaisho,T., andAkira, S. (2001). Toll-like
receptors and their signaling mech-
anism in innate immunity. Acta
Odontol. Scand. 59, 124–130.
Kamogawa, Y., Minasi, L. A., Carding,
S. R., Bottomly, K., and Flavell, R.
A. (1993). The relationship of IL-4-
and IFN gamma-producing T cells
studied by lineage ablation of IL-4-
producing cells. Cell 75, 985–995.
Kang, D. C., Gopalkrishnan, R. V.,
Wu, Q., Jankowsky, E., Pyle, A. M.,
and Fisher, P. B. (2002). mda-5:
an interferon-inducible putative
RNA helicase with double-stranded
RNA-dependent ATPase activity
and melanoma growth-suppressive
properties. Proc. Natl. Acad. Sci.
U.S.A. 99, 637–642.
Karanja, R., Ingonga, J., Mwangi, M.,
Mwala, D., Lugalia, R., Magambo, J.,
and Tonui, W. (2011). Immuniza-
tion with a combination of Leishma-
nia major lipophosphoglycan (LPG)
and Phlebotomus duboscqi salivary
gland lysates (SGLs) abrogates pro-
tective effect of LPG against L. major
in BALB/c mice.Afr. J. Health Sci. 18,
1–5.
Karplus, T. M., Jeronimo, S. M., Chang,
H., Helms, B. K., Burns, T. L., Mur-
ray, J. C.,Mitchell, A. A., Pugh, E.W.,
Braz, R. F., Bezerra, F. L., andWilson,
M. E. (2002). Association between
the tumor necrosis factor locus and
the clinical outcome of Leishmania
chagasi infection. Infect. Immun. 70,
6919–6925.
Kaur, T., Sobti, R. C., and Kaur, S.
(2011a). Cocktail of gp63 andHsp70
induces protection against Leishma-
nia donovani in BALB/c mice. Para-
site Immunol. 33, 95–103.
Kaur, J., Kaur, T., and Kaur, S. (2011b).
Studies on the protective efﬁcacy
and immunogenicity of Hsp70 and
Hsp83 based vaccine formulations
in Leishmania donovani infected
BALB/c mice. Acta Trop. 119,
50–56.
Kaye, P., and Scott, P. (2011). Leish-
maniasis: complexity at the host–
pathogen interface. Nat. Rev. Micro-
biol. 9, 604–615.
Kenney, R. T., Sacks, D. L., Gam,
A. A., Murray, H. W., and Sun-
dar, S. (1998). Splenic cytokine
responses in Indian kala-azar before
and after treatment. J. Infect. Dis.
177, 815–818.
Khalil, E. A., El Hassan, A. M., Zijl-
stra, E. E., Mukhtar, M. M., Ghalib,
H. W., Musa, B., Ibrahim, M. E.,
Kamil, A. A., Elsheikh, M., Babiker,
A., and Modabber, F. (2000). Auto-
claved Leishmania major vaccine
for prevention of visceral leishma-
niasis: a randomised, double-blind,
BCG-controlled trial in Sudan.
Lancet 356, 1565–1569.
Khalil, E. A., Musa, A. M., Modabber, F.,
and El-Hassan, A. M. (2006). Safety
and immunogenicity of a candi-
date vaccine for visceral leishmani-
asis (Alum-precipitated autoclaved
Leishmania major (BCG) in chil-
dren: an extended phase II study.
Ann. Trop. Paediatr. 26, 357–361.
Khamesipour, A., Dowlati, Y., Asil-
ian, A., Hashemi - Fesharki, R.,
Javadi, A., Noazin, S., and Modab-
ber, F. (2005). Leishmanization: use
of an old method for evaluation of
candidate vaccines against leishma-
niasis. Vaccine 23, 3642–3648.
Kobayashi, M., Fitz, L., Ryan, M.,
Hewick, R. M., Clark, S. C., Chan,
S., Loudon,R., Sherman, F., Perussia,
B., and Trinchieri, G. (1989). Iden-
tiﬁcation and puriﬁcation of natural
killer cell stimulatory factor (NKSF),
a cytokine with multiple biologic
effects on human lymphocytes. J.
Exp. Med.170, 827–845.
Kobukai, S., Kremers, G. J., Cobb, J.
G., Baheza, R., Xie, J., Kuley, A.,
Zhu, M., and Pham, W. (2011).
Induction of antitumor immu-
nity by dendritic cells loaded with
membrane-translocating mucin 1
Peptide antigen. Transl. Oncol. 4,
1–8.
Kubar, J., and Fragaki, K. (2005).
Recombinant DNA-derived Leish-
mania proteins: from the laboratory
to the ﬁeld. Lancet. Infect. Dis. 5,
107–114.
Kumari, S., Samant,M.,Misra,P.,Khare,
P., Sisodia, B., Shasany, A. K., and
Dube, A. (2008a). Th1-stimulatory
polyproteins of soluble Leishma-
nia donovani promastigotes ranging
from 89.9 to 97.1 kDa offers long-
lasting protection against experi-
mental visceral leishmaniasis. Vac-
cine 26, 5700–5711.
Kumari, S., Samant, M., Khare, P.,
Sundar, S., Sinha, S., and Dube,
A. (2008b). Induction of Th1-type
cellular responses in cured/exposed
Leishmania-infected patients and
hamsters against polyproteins of
soluble Leishmania donovani pro-
mastigotes ranging from 89.9 to 97.1
kDa. Vaccine 26, 4813–4818.
Kushawaha, P. K., Gupta, R., Sun-
dar, S., and Dube, A. (2011). Elon-
gation factor-2, a Th1 stimula-
tory protein of Leishmania dono-
vani, generates strong IFN-γ and
IL-12 response in cured Leishma-
nia-infected patients/hamsters and
protects hamsters against Leishma-
nia challenge. J. Immunol. 187,
6417–6427.
Lamb, J. R.,Zanders,E.D.,Lake,P.,Web-
ster,R. G., Eckels,D. D.,Woody, J. N.,
Green, N., Lerner, R. A., and Feld-
mann,M. (1984). Inhibition of T cell
proliferation by antibodies to syn-
thetic peptides. Eur. J. Immunol. 14,
153–157.
Lara, M. L., Layrisse, Z., Scorza, J.
V., Garcia, E., Stoikow, Z., Grana-
dos, J., and Bias, W. Immuno-
genetics of human American cuta-
neous leishmaniasis. (1991). Study
of HLA haplotypes in 24 families
from Venezuela. Hum. Immunol. 30,
129–135.
Larsen, M. H., Biermann, K., Chen,
B., Hsu, T., Sambandamurthy, V. K.,
Lackner, A. A., Aye, P. P., Didier,
P., Huang, D., Shao, L., Wei, H.,
Letvin, N. L., Frothingham, R.,
Haynes, B. F., Chen, Z. W., and
Jacobs,W. R. Jr. (2009). Efﬁcacy and
safety of live attenuated persistent
and rapidly cleared Mycobacterium
tuberculosis vaccine candidates in
non-human primates. Vaccine 27,
4709–4717.
Li, J., Hunter, C. A., and Farrell, J.
P. (1999). Anti-TGF-beta treatment
promotes rapid healing of Leish-
mania major infection in mice by
enhancing in vivo nitric oxide pro-
duction. J. Immunol. 162, 974–979.
Lima, K. M., Aparecida dos Santos,
A., Rodrigues, J. M. Jr., and Silva,
C. L. (2004). Vaccine adjuvant: it
makes the difference. Vaccine 22,
2374–2379.
Lodge, R., Diallo, T. O., and Descoteaux,
A. (2006). Leishmania donovani
lipophosphoglycan blocks NADPH
oxidase assembly at the phago-
some membrane. Cell. Microbiol. 8,
1922–1931.
Macedo, A. B., Sánchez-Arcila, J. C.,
Schubach, A. O., Mendonça, S. C.,
Marins-Dos-Santos, A., de Fatima
Madeira, M., Gagini, T., Pimentel,
M. I., and De Luca, P. M. (2012).
Multifunctional CD4+ T cells in
patients with American cutaneous
leishmaniasis. Clin. Exp. Immunol.
167, 505–513.
Madagi, S., Patil, V. M., Sadegh, S.,
Singh, A. K., Garwal, B., Baner-
jee, A., Talambedu, U., and Bhat-
tacharjee,B. (2011). Identiﬁcation of
membrane associated drug targets in
Borrelia burgdorferi ZS7- subtractive
genomics approach. Bioinformation
6, 356–359.
Mandage, R. H., and Wadnerkar, A.
S. (2010). Subtractive genomics
approach to identify potential ther-
apeutic targets in Leishmania dono-
vani. Int. J. Pharm. Bio Sci. 1, 1–7.
Martinon, F., and Tschopp, J. (2005).
NLRs join TLRs as innate sensors
of pathogens. Trends Immunol. 26,
447–454.
Masih, S., Arora, S. K., and Vasishta,
R. K. (2011). Efﬁcacy of Leishma-
nia donovani ribosomal P1 gene as
DNA vaccine in experimental vis-
ceral leishmaniasis. Exp. Parasitol.
129, 55–64.
Mazumder, T., Anam, K., and Ali, N.
(2004). A mixed Th1/Th2 response
elicited by a lip osomalformulation
of Leishmania vaccine instructs Th1
responses and resistance to Leishma-
nia donovani in susceptible BALB/c
mice. Vaccine 22, 1162–1171.
www.frontiersin.org May 2012 | Volume 3 | Article 99 | 15
Das and Ali Vaccination against visceral leishmaniasis
Mazumder, S., Maji, M., and Ali, N.
(2011a). Potentiating effects of MPL
on DSPC bearing cationic lipo-
somes promote recombinant GP63
vaccine efﬁcacy: high immuno-
genicity and protection. PLoS Negl.
Trop.Dis. 5,e1429. doi:10.1371/jour-
nal.pntd.0001429
Mazumder, S., Maji, M., Das, A., and
Ali, N. (2011b). Potency, efﬁcacy
and durability of DNA/DNA,
DNA/protein and protein/protein
based vaccination using gp63
against Leishmania donovani in
BALB/c mice. PLoS ONE 6, e14644.
doi:10.1371/journal.pone.0014644
Mazumder, S., Ravindran, R., Banerjee,
A., and Ali, N. (2007). Non-coding
pDNAbearingimmunostimula-
tory sequences co-entrapped with
leishmanial antigens in cationic
liposomes elicits almost complete
protection against experimental
visceral leishmaniasis in BALB/c
mice. Vaccine 25, 8771–8781.
McConville, M. J., Bacic, A., Mitchell,
G. F., and Handman, E. (1987).
Lipophosphoglycan of Leishmania
major that vaccinates against cuta-
neous leishmaniasis contains an
alkylglycerophosphoinositol lipid
anchor. Proc. Natl. Acad. Sci. U.S.A.
84, 8941–8945.
McShane, H., Behboudi, S.,
Goonetilleke, N., Brookes, R.,
and Hill, A. V. (2002). Protective
immunity against Mycobacterium
tuberculosis induced by dendritic
cells pulsed with both CD8 (+)-
and CD4(+)-T-cell epitopes from
antigen 85A. Infect. Immun. 70,
1623–1626.
McSorley, S. J., Xu, D., and Liew, F. Y.
(1997). Vaccine efﬁcacy of Salmo-
nella strains expressing glycoprotein
63 with different promoters. Infect.
Immun. 65, 171–178.
Meddeb-Garnaoui, A., Toumi, A., Ghe-
lis, H., Mahjoub, M., Louzir, H.,
and Chenik, M. (2010). Cellular
and humoral responses induced by
Leishmania histone H2B and its
divergent and conserved parts in
cutaneous and visceral leishmaniasis
patients, respectively. Vaccine 28,
1881–1886.
Melby, P., Ogden, G. B., Flores, H. A.,
Zhao, W., Geldmacher, C., Biediger,
N. M., Ahuja, S. K., Uranga, J., and
Melendez, M. (2000). Identiﬁcation
of vaccine candidates for experimen-
tal visceral leishmaniasis by immu-
nization with sequential fractions of
a cDNA expression library. Infect.
Immun. 68, 5595–5602.
Melby, P. C., Chandrasekar, B., Zhao,
W., and Coe, J. E. (2001a). The
hamster as a model of human
visceral leishmaniasis: progressive
disease and impaired generation of
nitric oxide in the face of a promi-
nent Th1-like cytokine response. J.
Immunol. 166, 1912–1920.
Melby, P. C., Yang, J., Zhao, W., Perez, L.
E., and Cheng, J. (2001b). Leishma-
nia donovani p36 (LACK) DNA vac-
cine is highly immunogenic but not
protective against experimental vis-
ceral leishmaniasis. Infect. Immun.
69, 4719–4725.
Mellman, I., and Steinman, R. M.
(2001). Dendritic cells: specialized
and regulated antigen processing
machines. Cell 106, 255–258.
Mendez, S., Tabbara, K., Belkaid, Y.,
Bertholet, S., Verthelyi, D., Klin-
man, D., Seder, R. A., and Sacks,
D. L. (2003). Coinjection with
CpG-containing immunostimula-
tory oligodeoxynucleotides reduces
the pathogenicity of a live vaccine
against cutaneous leishmaniasis but
maintains its potency and durability.
Infect. Immun. 71, 5121–5129.
Milano, S., Di Bella, G., D’Agostino, P.,
Barbera, C., Caruso, R., La Rosa, M.,
Ferlazzo, V., Vitale, G., La Russa, C.,
Gambino, G., Chifari, N., Mansueto,
S., and Cillari, E. (2002). IL-15 in
human visceral leishmaniasis caused
by Leishmania infantum. Clin. Exp.
Immunol. 127, 360–365.
Misra, A., Dube, A., Shrivastava, B.,
Sharma, P., Shrivastava, J. K., and
Katiyar, J. C. (2001). Successful vac-
cination against Leishmania dono-
vani infection in Indian langur using
alum-precipitated autoclaved Leish-
mania major with BCG. Vaccine 19,
3485–3492.
Mizbani, A., Taheri, T., Zahedifard, F.,
Taslimi, Y., Azizi, H., Azadmanesh,
K., Papadopoulou, B., and Rafati,
S. (2009). Recombinant Leishmania
tarentolae expressing the A2 viru-
lence gene as a novel candidate vac-
cine against visceral leishmaniasis.
Vaccine 28, 53–62.
Mizbani, A., Taslimi, Y., Zahedifard, F.,
Taheri, T., and Rafati, S. (2011).
Effect of A2 gene on infectivity of
the nonpathogenic parasite Leish-
mania tarentolae. Parasitol. Res. 109,
793–799.
Mohamed, H. S., Ibrahim, M. E., Miller,
E. N., Peacock, C. S., Khalil, E. A.,
Cordell, H. J., Howson, J. M., El Has-
san, A. M., Bereir, R. E., and Black-
well, J. M. (2003). Genetic suscepti-
bility to visceral leishmaniasis in The
Sudan: linkage and association with
IL4 and IFNGR1. Genes Immun. 4,
351–355.
Mohamed, H. S., Ibrahim, M. E., Miller,
E. N., White, J. K., Cordell, H. J.,
Howson, J. M., Peacock, C. S., Khalil,
E. A., El Hassan, A. M., and Black-
well, J. M. (2004). SLC11A1 (for-
merly NRAMP1) and susceptibil-
ity to visceral leishmaniasis in The
Sudan.Eur. J.Hum.Genet. 12,66–74.
Mohebali, M., Khamesipour, A.,
Mobedi, I., Zarei, Z., and Hashemi-
Fesharki, R. (2004). Double blind
randomized efﬁcacy ﬁeld trial of
alum precipitated autoclaved Leish-
mania major vaccine mixed with
BCG against canine visceral leish-
maniasis in Meshkin-Shahr district,
I.R. Iran. Vaccine 22, 4097–4100.
Moll,H., andBerberich,C. (2001).Den-
dritic cell-based vaccination strate-
gies: induction of protective immu-
nity against leishmaniasis. Immuno-
biology 204, 659–666.
Momeni, A. Z., and Aminjavaheri, M.
(1994). Clinical picture of cutaneous
leishmaniasis in Isfahan, Iran. Int. J.
Dermatol. 33, 260–265.
Momeni, A. Z., Jalayer, T., Emamjomeh,
T.,Khamesipour,A.,Zicker, F.,Ghas-
semi, R. L., Dowlati, Y., Shariﬁ,
I., Aminjavaheri, M., Shaﬁei, I.,
Alimohammadian,M. H.,Hashemi-
Fesharki, R., Nasseri, K., Godal,
T., Smith, P. G., and Modabber,
F. (1999). A randomized double
blind controlled trial of a killed
L. major vaccine plus BCG against
zoonotic cutaneous leishmaniasis in
Iran. Vaccine 17, 466–472.
Morris, R. V., Shoemaker, C. B., David,
J. R., Lanzaro, G. C., and Titus, R.
G. (2001). Sandﬂy maxadilan exac-
erbates infection with Leishmania
major and vaccinating against it pro-
tects against L. major infection. J.
Immunol. 167, 5226–5230.
Moser, M., and Murphy, K. M. (2000).
Dendritic cell regulation of TH1-
TH2 development. Nat. Immunol. 1,
199–205.
Mukherjee, M., Bhattacharyya, A., and
Duttagupta, S. (2002). Serodiagnos-
tic and immunoprophylactic poten-
tial of a 78kDa protein of Leishmania
donovani of Indian origin. Med. Sci.
Monit. 8, 117–122.
Müller, I., Fruth, U., and Louis, J. A.
(1992). Immunobiology of experi-
mental leishmaniasis. Med. Micro-
biol. Immunol. 181, 1–12.
Murray, H. W., and Cartelli, D. M.
(1983). Killing of intracellular
Leishmania donovani by human
mononuclear phagocytes. Evidence
for oxygen-dependent and -
independent leishmanicidal activity.
J. Clin. Invest. 72, 32–44.
Murray, H. W., Rubin, B. Y., and
Rothermel, C. D. (1983). Killing
of intracellular Leishmania donovani
by lymphokine-stimulated human
mononuclear phagocytes. Evidence
that interferon-gamma is the activat-
ing lymphokine. J. Clin. Invest. 72,
1506–1510.
Murray, H. W., Squires, K. E., Miralles,
C. D., Stoeckle,M.Y.,Granger,A.M.,
Granelli-Piperno, A., and Bogdan,
C. (1992). Acquired resistance and
granuloma formation in experimen-
tal visceral leishmaniasis. Differen-
tial T cell and lymphokine roles in
initial versus established immunity.
J. Immunol. 148, 1858–1863.
Murugaiyan, G., Mittal, A., Lopez-
Diego, R.,Maier, L. M.,Anderson,D.
E., and Weiner, H. L. (2009). IL-27
is a key regulator of IL-10 and IL-17
production by human CD4+ T cells.
J. Immunol. 183, 2435–2443.
Musa, A. M., Khalil, E. A., Mahgoub, F.
A., Elgawi, S. H., Modabber, F., Elka-
daru, A. E., Aboud, M. H., Noazin,
S., Ghalib, H. W., and El-Hassan, A.
M. (2008). Immunochemotherapy
of persistent post-kala-azar dermal
leishmaniasis: a novel approach to
treatment. Trans. R. Soc. Trop. Med.
Hyg. 102, 58–63.
Nadim, A., Javadian, E., Tahvildar-
Bidruni, G., and Ghorbani, M.
(1983). Effectiveness of leishman-
ization in the control of cutaneous
leishmaniasis. Bull. Soc. Pathol. Exot.
Filiales 76, 377–383.
Nagill, R., and Kaur, S. (2010).
Enhanced efﬁcacy and immuno-
genicity of 78kDa antigen formu-
lated in various adjuvants against
murine visceral leishmaniasis. Vac-
cine 28, 4002–4012.
Nakhasi, H. L., Zheng, D., Callahan, L.,
Dave, J. R., and Liu, T. Y. (1989).
Rubella virus: mechanism of attenu-
ation in the vaccine strain (HPV77).
Virus Res. 13, 231–243.
Napolitani, G., Rinaldi, A., Bertoni, F.,
Sallusto, F., and Lanzavecchia, A.
(2005). Selected Toll like receptor
agonist combinations synergistically
trigger a T helper type 1-polarizing
program in dendritic cells. Nat.
Immunol. 6, 769–776.
Nateghi Rostami, M., Keshavarz Valian,
H., Eskandari, S. E., Miramin
Mohammadi, A., Shahrestani, S. T.,
Sarraf-Nejad, A., and Khamesipour,
A. (2010). Differential in vitro
CD4+/CD8+ T-cell response to live
vs. killed Leishmania major. Parasite
Immunol. 32, 101–110.
Nicolas, L., Prina, E., Lang, T., and
Milon, G. (2002). Real-time PCR
for detection and quantitation of
Leishmania in mouse tissues. J. Clin.
Microbiol. 40, 1666–1669.
Nieto, A., Domínguez-Bernal, G.,
Orden, J. A., De La Fuente, R.,
Madrid-Elena, N., and Carrión, J.
(2011). Mechanisms of resistance
Frontiers in Immunology | Microbial Immunology May 2012 | Volume 3 | Article 99 | 16
Das and Ali Vaccination against visceral leishmaniasis
and susceptibility to experimental
visceral leishmaniosis: BALB/c
mouse versus syrian hamster model.
Vet. Res. 42, 39.
Nogueira, F. S., Moreira, M. A., Borja-
Cabrera, G. P., Santos, F. N., Menz,
I., Parra, L. E., Xu, Z., Chu, H.
J., Palatnik-de-Sousa, C. B., and
Luvizotto, M. C. (2005). Leishmune
vaccine blocks the transmission
of canine visceral leishmaniasis:
absence of Leishmania parasites in
blood, skin and lymph nodes of vac-
cinated exposed dogs. Vaccine 23,
4805–4810.
Nylén,S., andAkuffo,H. (2009). Tracing
immunity to human leishmaniasis.
Future Microbiol. 4, 241–254.
Nylén, S., Maasho, K., Söderstrom,
K., Ilg, T., and Akuffo, H. (2003).
Live Leishmania promastigotes can
directly activate primary human
natural killer cells to produce
interferon-gamma. Clin. Exp.
Immunol. 131, 457–467.
Nylén, S., Maurya, R., Eidsmo, L., Man-
andhar, K. D., Sundar, S., and Sacks,
D. (2007). Splenic accumulation of
IL-10 mRNA in T cells distinct from
CD4+CD25+ (Foxp3) regulatory T
cells in human visceral leishmania-
sis. J. Exp. Med. 204, 805–817.
Okwor, I., and Uzonna, J. (2008). Per-
sistent parasites and immunologic
memory in cutaneous leishmaniasis:
implications for vaccine designs and
vaccination strategies. Immunol. Res.
41, 123–136.
Olivier, M., Gregory, D. J., and For-
get, G. (2005). Subversion mecha-
nisms by which Leishmania para-
sites can escape the host immune
response: a signaling point of
view Clin. Microbiol. Rev. 18,
293–305.
Ozbilge, H., Aksoy, N., Gurel, M. S.,
and Yazar, S. (2006). IgG and IgG
subclass antibodies in patients with
active cutaneous leishmaniasis. J.
Med. Microbiol. 55, 1329–1331.
Palatnik de Sousa, C. B., Moreno, M.
B., Paraguai de Souza, E., and Boro-
jevic, R. (1994a). The FML-vaccine
(Fucose–Mannose Ligand) protects
hamsters from experimental Kala-
Azar. J. Braz. Assoc. Adv. Sci. 46,
290–296.
Palatnik de Sousa, C. B., Paraguai
de Souza, E., Gomes, E. M., and
Borojevic, R. (1994b). Experimen-
tal murine Leishmania donovani
infection: immunoprotection by the
fucose-mannose ligand (FML).Braz.
J. Med. Biol. Res. 27, 547–555.
Palatnik de Sousa, C. B., Gomes, E. M.,
de Souza, E. P., dos Santos, W. R.,
de Macedo, S. R., de Medeiros, L.
V., and Luz, K. (1996). The FML
(fucose mannose ligand) of Leish-
mania donovani: a new tool in diag-
nosis, prognosis, transfusional con-
trol and vaccination against human
kala-azar. Rev. Soc. Bras. Med. Trop.
29, 153–163.
Palatnik de Sousa, C. B., Santos, W.
R., Casas, C. P., Paraguai de Souza,
E., Tinoco, L. W., da Silva, B.
P., Palatnik, M., and Parente, J.
P. (2004). Protective vaccination
against murine visceral leishmania-
sis using aldehyde-containing Quil-
laja saponaria sapogenins. Vaccine
22, 2470–2479.
Papadopoulou, B., Roy, G., Breton, M.,
Kündig, C., Dumas, C., Fillion, I.,
Singh, A. K., Olivier, M., and Ouel-
lette, M. (2002). Reduced infectivity
of a Leishmania donovani biopterin
transporter genetic mutant and
its use as an attenuated strain
for vaccination. Infect. Immun. 70,
62–68.
Paraguai-de-Souza, E., Bernardo, R. R.,
Palatnik, M., and Palatnik-deSousa,
C. B. (2001). Vaccination of Balb/c
mice against experimental visceral
leishmaniasis with the GP36 glyco-
protein antigenof Leishmania dono-
vani. Vaccine 19, 3104–3115.
Parra, L. E., Borja-Cabrera, G. P., San-
tos, F. N., Souza, L. O., Palatnik-
de-Sousa, C. B., and Menz, I.
(2007). Safety trial using the Leish-
mune vaccine against canine visceral
leishmaniasis in Brazil. Vaccine 25,
2180–2186.
Pearson, R. D., and Sousa, A. Q. (1996).
Clinical spectrum of leishmaniasis.
Clin. Infect. Dis. 22, 1–13.
Perumal,D., Lim,C. S., Sakharkar,K. R.,
and Sakharkar, M. K. (2007). Differ-
ential genome analyses of metabolic
enzymes in Pseudomonas aerugi-
nosa for drug target identiﬁcation.
In Silico Biol. 7, 453–465.
Peters, N., and Sacks, D. (2006).
Immune privilege in sites of chronic
infection: Leishmania and regula-
tory T cells. Immunol. Rev. 213,
159–179.
Petzl-Erler, M. L., Belich, M. P., and
Queiroz-Telles, F. (1991). Asso-
ciation of mucosal leishmaniasis
with HLA. Hum. Immunol. 32,
254–260.
Piccioli, D., Sbrana, S., Melandri, E.,
andValiante,N. M. (2002). Contact-
dependent stimulation and inhibi-
tion of dendritic cells by natural
killer cells. J. Exp.Med. 195,335–341.
Pitta, M. G., Romano, A., Cabantous,
S., Henri, S., Hammad, A., Kouriba,
B., Argiro, L., el Kheir,M., Bucheton,
B., Mary, C., El-Saﬁ, S. H., and Des-
sein, A. (2009). IL-17 and IL-22 are
associated with protection against
human kala azar caused by Leish-
mania donovani. J. Clin. Invest. 119,
2379–2387.
Praveena,A., Sindhuja,R.,Anuradha,V.,
and Habeeb, S. K. M. (2011). Puta-
tive drug target identiﬁcation for
chlamydia trachomatis: an in silico
proteome analysis. Int. J. Biomed.
Res. 2, 151–160.
Prina, E., Abdi, S. Z., Lebastard,M., Per-
ret, E, Winter, N., and Antoine, J. C.
(2004). Dendritic cells as host cells
for the promastigote and amastig-
ote stages of Leishmania amazonen-
sis: the role of opsonins in parasite
uptake and dendritic cell matura-
tion. J. Cell. Sci. 117, 315–325.
Rachamim, N., and Jaffe, C. L. (1993).
Pure protein from Leishmania dono-
vani protectsmice against both cuta-
neous and visceral leishmaniasis. J.
Immunol. 150, 2322–2331.
Rafati, S., Zahedifard, F., and Nazgouee,
F. (2006). Prime-boost vaccination
using cysteine proteinases type I
and II of Leishmania infantum con-
fers protective immunity in murine
visceral leishmaniasis. Vaccine 24,
2169–2175.
Raman, V. S., Bhatia, A., Picone, A.,
Whittle, J., Bailor, H. R., O’Donnell,
J., Pattabhi, S., Guderian, J. A.,
Mohamath, R., Duthie, M. S., and
Reed, S. G. (2010). Applying TLR
synergy in immunotherapy: impli-
cations in cutaneous leishmaniasis.
J. Immunol. 185, 1701–1710.
Ravindran, R., Anam, K., Bairagi, B. C.,
Saha, B., Pramanik, N., Guha, S. K.,
Goswami, R. P., Banerjee, D., and
Ali, N. (2004). Characterization of
immunoglobulin G and its subclass
response to Indian kala-azar infec-
tion before and after chemotherapy.
Infect. Immun. 72, 863–870.
Ravindran, R., Bhowmick, S., Das, A.,
and Ali, N. (2010). Comparison
of BCG, MPL and cationic lipo-
some adjuvant systems in leish-
manial antigen vaccine formula-
tions against murine visceral leish-
maniasis. BMC Microbiol. 10, 181.
doi:10.1186/1471-2180-10-181
Ravindran, R., Maji, M., and Ali,
N. (2012). Vaccination with lipo-
somal leishmanial antigens adju-
vanted with MPL-TDM confers
long-term protection against vis-
ceral leishmaniasis through human
adminstrable route. Mol. Pharm. 9,
59–70.
Reed, S. G., Coler, R. N., and Campos-
Neto, A. (2003). Development of
a leishmaniasis vaccine: the impor-
tance of MPL. Expert Rev. Vaccines
2, 239–252.
Remer, K. A., Apetrei, C., Schwarz,
T., Linden, C., and Moll, H.
(2007). Vaccination with plasmacy-
toid dendritic cells induces protec-
tion against infection with Leishma-
nia major in mice. Eur. J. Immunol.
37, 2463–2473.
Resende, D. M., Caetano, B. C., Dutra,
M. S., Penido, M. L., Abrantes,
C. F., Verly, R. M., Resende, J.
M., Piló-Veloso, D., Rezende, S. A.,
Bruna-Romero, O., Fernandes, A. P.,
and Gazzinelli, R. T. (2008). Epi-
tope mapping and protective immu-
nity elicited by adenovirus express-
ing the Leishmania amastigote spe-
ciﬁc A2 antigen: correlation with
IFN-gamma and cytolytic activ-
ity by CD8+ T cells. Vaccine 26,
4585–4593.
Rohtagi, A., Agarwal, S. K., Bose, M.,
Chattopadhya, D., and Saha, K.
(1996). Blood, bone marrow and
splenic lymphocyte subset proﬁles in
Indian visceral leishmaniasis. Trans.
R. Soc. Trop. Med. Hyg. 90, 431–434.
Russo, D. M., Jardim, A, Carvalho, E.
M., Sleath, P. R., Armitage, R. J.,
Olafson, R. W., and Reed, S. G.
(1993). Mapping human T cell epi-
topes in Leishmania gp63. Identiﬁ-
cation of cross-reactive and species-
speciﬁc epitopes. J. Immunol. 150,
932–939.
Ryan, J. R., Smithyman, A. M.,
Rajasekariah, G. H., Hochberg,
L., Stiteler, J. M., and Mar-
tin, S. K. (2002). Enzyme-linked
immunosorbent assay based on sol-
uble promastigote antigen detects
immunoglobulin M (IgM) and IgG
antibodies in sera from cases of vis-
ceral and cutaneous leishmaniasis. J.
Clin. Microbiol. 40, 1037–1043.
Sachdeva, R., Banerjea, A. C., Malla, N.,
and Dubey, M. L. (2009). Immuno-
genicity and efﬁcacy of single anti-
gen Gp63, polytope and polytope
HSP70 DNA vaccines against vis-
ceral Leishmaniasis in experimental
mouse model. PLoS One 4, e7880.
Sacks, D. L. (2001). Leishmania-sand
ﬂy interactions controlling species-
speciﬁc vector competence. Cell.
Microbiol. 3, 189–196.
Sacks, D. L., Lal, S. L., Shrivastava, S. N.,
Blackwell, J., and Neva, F. A. (1987).
An analysis of T cell responsiveness
in Indian kala-azar. J. Immunol. 138,
908–913.
Saha, S., Mondal, S., Banerjee, A.,
Ghose, J, Bhowmick, S., and Ali,
N. (2006). Immune responses in
kala-azar. Indian J. Med. Res. 123,
245–266.
Saha, S., Mondal, S., Ravindran, R.,
Bhowmick, S., Modak, D., Mallick,
S., Rahman, M., Kar, S., Goswami,
R., Guha, S. K., Pramanik, N., Saha,
B., and Ali, N. (2007). IL-10- and
www.frontiersin.org May 2012 | Volume 3 | Article 99 | 17
Das and Ali Vaccination against visceral leishmaniasis
TGF-beta-mediated susceptibility in
kala-azar and post-kala-azar der-
mal leishmaniasis: the signiﬁcance
of amphotericin B in the control
of Leishmania donovani infection in
India. J. Immunol. 179, 5592–5603.
Sakharkar, K. R., Sakharkar, M. K.,
and Chow, V. T. K. (2004). A
novel genomics approach for the
identiﬁcation of drug targets in
pathogens, with special reference to
Pseudomonas aeruginosa. In silico
Biol. (Gedrukt) 4, 0028.
Saldarriaga, O. A., Travi, B. L., Park, W.,
Perez, L. E., and Melby, P. C. (2006).
Immunogenicity of a multicompo-
nent DNA vaccine against visceral
leishmaniasis in dogs. Vaccine 24,
1928–1940.
Samant, M., Gupta, R., Kumari, S.,
Misra, P., Khare, P., Kushawaha, P.
K., Sahasrabuddhe, A. A., and Dube,
A. (2009). Immunization with the
DNA-encoding N-terminal domain
of proteophosphoglycan of Leish-
mania donovani generates Th1-type
immunoprotective response against
experimental visceral leishmaniasis.
J. Immunol. 183, 470–479.
Sanabria,M.X.,Vargas-Inchaustegui,D.
A., Xin, L., and Soong, L. (2008).
Role of natural killer cells in mod-
ulating dendritic cell responses to
Leishmania amazonensis infection.
Infect. Immun. 76, 5100–5109.
Santos, W. R., de Lima, V. M., de
Souza, E. P., Bernardo, R. R., Palat-
nik, M., and Palatnik de Sousa, C.
B. (2002). Saponins, IL12 and BCG
adjuvant in the FML-vaccine formu-
lation against murine visceral leish-
maniasis. Vaccine 21, 30–43.
Santos, W. R., Paraguai de Souza, E.,
Palatnik, M., and Palatnik de Sousa,
C. B. (1999). Vaccination of Swiss
albino mice against experimental
visceral leishmaniasis with the FML
antigen of Leishmania donovani.
Vaccine 17, 2554–2561.
Saraiva, E. M., de Figueiredo Bar-
bosa, A., Santos, F. N., Borja-
Cabrera, G. P., Nico, D., Souza, L.
O., de Oliveira Mendes-Aguiar, C.,
de Souza, E. P., Fampa, P., Parra,
L. E., Menz, I., Dias, J. G. Jr.,
de Oliveira, S. M., and Palatnik-
de-Sousa, C. B. (2006). The FML-
vaccine (Leishmune) against canine
visceral leishmaniasis: a transmis-
sion blocking vaccine. Vaccine 24,
2423–2431.
Scharton, T. M., and Scott, P. (1993).
Natural killer cells are a source of
interferon gamma that drives differ-
entiation of CD4+T cell subsets and
induces early resistance to Leishma-
nia major in mice. J. Exp. Med. 178,
567–577.
Scott, P. (2003). Development and reg-
ulation of cell mediated immu-
nity in experimental leishmaniasis.
Immunol. Res. 27, 489–498.
Selvapandiyan, A., Dey, R., Nylen,
S., Duncan, R., Sacks, D., and
Nakhasi, H. L. (2009). Intracellu-
lar replication-deﬁcient Leishmania
donovani induces long lasting pro-
tective immunity against visceral
leishmaniasis. J. Immunol. 183,
1813–1820.
Shadab, M., and Ali, N. (2011). Eva-
sion of host defence by Leishma-
nia donovani: subversion of signal-
ing pathways. Mol. Biol. Int. 2011,
343961.
Shariﬁ, I., Fekri, A. R., Aﬂatonian,
M. R., Khamesipour, A., Nadim,
A., Mousavi, M. R., Momeni,
A. Z., Dowlati, Y., Godal, T.,
Zicker, F., Smith, P. G., and
Modabber, F. (1998). Randomised
vaccine trial of single dose of
killed L. major plus BCG against
anthroponotic cutaneous leishman-
isis in Bam, Iran. Lancet 351,
1540–1543.
Sharma, A., and Madhubala, R. (2009).
Ubiquitin conjugation of open read-
ing frame F DNA vaccine leads
to enhanced cell-mediated immune
response and induces protection
against both antimony-susceptible
and -resistant strains of Leishma-
nia donovani. J. Immunol. 183,
7719–7731.
Sharma, M. C., Gupta, A. K., Das, V.
N., Verma, N., Kumar, N., Saran,
R., and Kar, S. K. (2000). Leishma-
nia donovani in blood smears of
asymptomatic persons. Acta Trop.
76, 195–196.
Silvestre, R., Cordeiro-Da-Silva, A.,
Santarém, N., Vergnes, B., Sereno,
D., and Ouaissi, A. (2007). SIR2-
deﬁcient Leishmania infantum
induces a deﬁned IFN-gamma/IL-
10 pattern that correlates with
protection. J. Immunol. 179,
3161–3170.
Sinha, S., Sundaram, S., Singh, A. P.,
and Tripathi, A. (2011). A gp63
based vaccine candidate against vis-
ceral leishmaniasis. Bioinformation
5, 320–325.
Skeiky, Y. A., Coler, R. N., Brannon, M.,
Stromberg, E., Greeson, K., Crane,
R. T., Webb, J. R., Campos-Neto,
A., and Reed, S. G. (2002). Protec-
tive efﬁcacy of a tandemly linked,
multi-subunit recombinant leish-
manial vaccine (Leish-111f) formu-
lated in MPL adjuvant. Vaccine 20,
3292–3303.
Soto, M., Requena, J. M., Quijada, L.,
Perez, M. J., Nieto, C. G., Guzman,
F., Patarroyo, M. E., and Alonso, C.
(1999). Antigenicity of the Leish-
mania infantum histones H2B and
H4 during canine viscerocutaneous
leishmaniasis. Clin. Exp. Immunol.
115, 342–349.
Späth, G. F., Epstein, L., Leader, B.,
Singer, S. M., Avila, H. A., Turco,
S. J., and Beverley, S. M. (2000).
Lipophosphoglycan is a virulence
factor distinct from related glyco-
conjugates in the protozoan parasite
Leishmania major. Proc. Natl. Acad.
Sci. U.S.A. 97, 9258–9263.
Spitzer, N., Jardim, A., Lippert, D., and
Olafson, R. W. (1999). Long-term
protection of mice against Leishma-
nia major with a synthetic peptide
vaccine. Vaccine 17, 1298–1300.
Squires, K. E., Rosenkaimer, F., Sher-
wood, J. A., Forni, A. L., Were,
J. B., and Murray, H. W. (1993).
Immunochemotherapy for visceral
leishmaniasis: a controlled pilot trial
of antimony versus antimony plus
interferon-gamma.Am. J. Trop.Med.
Hyg. 48, 666–669.
Stäger, S., Alexander, J., Kirby, A. C.,
Botto, M., Rooijen, N. V., Smith, D.
F., Brombacher, F., and Kaye, P. M.
(2003). Natural antibodies and com-
plement are endogenous adjuvants
for vaccine-induced CD8+ T-cell
responses. Nat. Med. 9, 1287–1292.
Stager, S., Smith, D. F., and Kaye,
P. M. (2000). Immunization with
a recombinant stage-regulated sur-
face protein from Leishmania dono-
vani induces protection against vis-
ceral leishmaniasis. J. Immunol. 165,
7064–7071.
Stern, A. S., Podlaski, F. J., Hul-
mes, J. D., Pan, Y. C., Quinn,
P. M., Wolitzky, A. G., Familletti,
P. C., Stremlo, D. L., Truitt, T.,
Chizzonite, R., and Gately, M. K.
(1990). Puriﬁcation to homogeneity
and partial characterization of cyto-
toxic lymphocyte maturation fac-
tor from human B-lymphoblastoid
cells. Proc. Natl. Acad. Sci. U.S.A. 87,
6808–6812.
Stobie, L., Gurunathan, S., Prussin,
C., Sacks, D. L., Glaichenhaus,
N., Wu, C.-Y., and Seder, R. A.
(2000). The role of antigen and
IL-12 in sustaining Th1 memory
cells in vivo: IL-12 is required
to maintain memory/effector Th1
cells sufﬁcient to mediate protec-
tion to an infectious parasite chal-
lenge.Proc. Natl. Acad. Sci. U.S.A. 97,
8427–8432.
Sukumaran, B., Tewary, P., Saxena, S.,
and Madhubala, R. (2003). Vacci-
nation with DNA encoding ORFF
antigen confers protective immunity
in mice infected with Leishmania
donovani. Vaccine 21, 1292–1299.
Sundar, S., and Murray, H. W. (1995).
Effect of treatment with interferon-
gamma alone in visceral leishmani-
asis. J. Infect. Dis. 172, 1627–1629.
Sundar, S., Reed, S. G., Sharma, S.,
Mehrotra, A., and Murray, H. W.
(1997a). Circulating T helper 1
(Th1) cell- and Th2 cell-associated
cytokines in Indian patients with
visceral leishmaniasis. Am. J. Trop.
Med. Hyg. 56, 522–525.
Sundar, S., Singh, V. P., Sharma, S.,
Makharia, M. K., and Murray, H.
W. (1997b). Response to interferon-
gamma plus pentavalent antimony
in Indian visceral leishmaniasis. J.
Infect. Dis. 176, 1117–1119.
Sundar, S., Rosenkaimer, F., Lesser,
M. L., and Murray, H. W. (1995).
Immunochemotherapy for a sys-
temic intracellular infection: accel-
erated response using interferon-
gamma in visceral leishmaniasis. J.
Infect. Dis. 171, 992–996.
Sundar, S., Rosenkaimer, F., and Mur-
ray, H. W. (1994). Successful treat-
ment of refractory visceral leishma-
niasis in India using antimony plus
interferon-gamma. J. Infect. Dis. 170,
659–662.
Tejle, K., Lindroth, M., Magnus-
son, K. E., and Rasmusson, B.
(2008). Wild-type Leishmania dono-
vani promastigotes block matu-
ration, increase integrin expres-
sion and inhibit detachment of
human monocyte-derived dendritic
cells – the inﬂuence of phospho-
glycans. FEMS Microbiol. Lett. 279,
92–102.
Tewary, P., Jain, M., Sahani, M.
H., Saxena, S., and Madhubala,
R. (2005). A heterologous prime-
boost vaccination regimen using
ORFF DNA and recombinant ORFF
protein confers protective immu-
nity against experimental visceral
leishmaniasis. J. Infect. Dis. 191,
2130–2137.
Tewary, P., Pandya, J., Mehta, J.,
Sukumaran, B., and Madhubala,
R. (2004a). Vaccination with
Leishmania soluble antigen and
immunostimulatory oligodeoxynu-
cleotides induces speciﬁc immunity
and protection against Leishmania
donovani infection. FEMS Immunol.
Med. Microbiol. 4, 241–248.
Tewary, P., Sukumaran, B., Saxena,
S., and Madhubala, R. (2004b).
Immunostimulatory oligodeoxynu-
cleotides are potent enhancers of
protective immunity in mice immu-
nized with recombinant ORFF
leishmanial antigen. Vaccine 22,
3053–3060.
Titus, R. G., and Ribeiro, J. M. (1988).
Salivary gland lysates from the sand
Frontiers in Immunology | Microbial Immunology May 2012 | Volume 3 | Article 99 | 18
Das and Ali Vaccination against visceral leishmaniasis
ﬂy Lutzomyia longipalpis enhance
Leishmania infectivity. Science 239,
1306.
Tonui, W. K., Mbati, P. A., Anjili, J. O.,
Orago,A. S.,Turco, S. J.,Githure, J. I.,
and Koech, D. K. (2001). Transmis-
sion blocking vaccine studies in lel-
ishmaniasis: I. Lipophosphoglycan is
a promising transmission blocking
vaccine molecule against cutaneous
leishmaniasis. East Afr. Med. J. 78,
84–89.
Tracey, K. J., Wei, H., Manogue, K. R.,
Fong, Y., Hesse, D. G., Nguyen, H.
T., Kuo, G. C., Beutler, B., Cotran,
R. S., Cerami, A., and Lowry, S.
F. (1988). Cachectin/tumor necro-
sis factor induces cachexia, anemia,
and inﬂammation. J. Exp. Med. 167,
1211–1227.
Trinchieri, G. (1993). Interleukin-12
and its role in the generation of TH1
cells. Immunol. Today 14, 335–338.
Tsagozis, P., Karagouni, E., and Dot-
sika,E. (2004).Dendritic cells pulsed
with peptides of gp63 induce dif-
ferential protection against experi-
mental cutaneous leishmaniasis. Int.
J. Immunopathol. Pharmacol. 17,
343–352.
Valenzuela, J. G., Garﬁeld, M., Row-
ton, E. D., and Pham, V. M. (2004).
Identiﬁcation of the most abundant
secreted proteins from the salivary
glands of the sand ﬂy Lutzomyia
longipalpis, vector of Leishmania
chagasi. J. Exp. Biol. 7, 3717–3729.
Vélez, I. D.,Gilchrist, K.,Arbelaez,M. P.,
Rojas, C. A., Puerta, J. A., Antunes,
C. M., Zicker, F., and Modabber,
F. (2005). Failure of a killed Leish-
mania amazonensis vaccine against
American cutaneous leishmaniasis
in Colombia. Trans. R. Soc. Trop.
Med. Hyg. 99, 593–598.
Vélez, I. D., Gilchrist, K., Martínez, S.,
Ramírez-Pineda, J. R., Ashman, J. A.,
Alves, F. P., Coler, R. N., Bogatzki,
L. Y., Kahn, S. J., Beckmann, A. M.,
Cowgill, K. D., Reed, S. G., and
Piazza, F. M. (2009). Safety and
immunogenicity of a deﬁned vac-
cine for the prevention of cutaneous
leishmaniasis. Vaccine 28, 329–337.
Vinet, A. F., Fukuda, M., Turco, S.
J., and Descoteaux, A. (2009).
The Leishmania donovani lipophos-
phoglycan excludes the vesicular
proton-ATPase from phagosomes
by impairing the recruitment of
synaptotagmin V. PLoS Pathog. 5,
e1000628. doi:10.1371/journal.ppat.
1000628
Vouldoukis, I., Bécherel, P. A., Riveros-
Moreno, V., Arock, M., da Silva, O.,
Debré, P., Mazier, D., and Mossalayi,
M. D. (1997). Interleukin-10 and
interleukin-4 inhibit intracellular
killing of Leishmania infantum
and Leishmania major by human
macrophages by decreasing nitric
oxide generation. Eur. J. Immunol. 4,
860–865.
Walker, P. S., Scharton-Kersten, T.,
Krieg, A. M., Love-Homan, L., Row-
ton, E. D., Udey, M. C., and
Vogel, J. C. (1999). Immunostim-
ulatory oligodeoxynucleotides pro-
mote protective immunity and pro-
vide systemic therapy for leishmani-
asis via IL-12- and IFN-γ-dependent
mechanisms. Proc. Natl. Acad. Sci.
U.S.A. 96, 6970–6975.
Walton, B. C., and Valverde, L.
(1979). Racial difference in espun-
dia. Ann. Trop. Med. Parasitol. 73,
23–29.
Wang, Y., Chen, Y., Xin, L., Beverley,
S. M., Carlsen, E. D., Popov, V.,
Chang, K. P., Wang, M., and Soong,
L. (2011). Differential microbicidal
effects of human histone proteins
H2A and H2B on Leishmania pro-
mastigotes and amastigotes. Infect.
Immun. 79, 1124–1133.
Weigle, K., and Saravia, N. G. (1996).
Natural history, clinical evolution,
and the host–parasite interaction in
NewWorld cutaneous leishmaniasis.
Clin. Dermatol. 14, 433–450.
Wilson, M. E., Jeronimo, S. M.,
and Pearson, R. D. (2005).
Immunopathogenesis of infection
with the visceralizing Leishmania
species. Microb. Pathog. 38, 147–160.
Woelbing, F., Kostka, S. L., Moelle, K.,
Belkaid, Y., Sunderkoetter, C., Ver-
beek, S., Waisman, A., Nigg, A. P.,
Knop, J., Udey, M. C., and von Ste-
but, E. (2006). Uptake of Leish-
mania major by dendritic cells is
mediated by Fcgamma receptors
and facilitates acquisition of pro-
tective immunity. J. Exp. Med. 203,
177–188.
Wu, W., Huang, L., and Mendez, S.
(2010). A live Leishmania major vac-
cine containing CpG motifs induces
the de novo generation of Th17 cells
in C57BL/6 mice. Eur. J. Immunol.
40, 2517–2527.
Yam, K. K., Hugentobler, F., Pouliot,
P., Stern, A. M., Lalande, J. D.,
Matlashewski, G., Olivier, M., and
Cousineau, B. (2011). Generation
and evaluation of A2-expressing
Lactococcus lactis live vaccines
against Leishmania donovani in
BALB/c mice. J. Med. Microbiol. 60,
1248–1260.
Zadeh-Vakili, A., Taheri, T., Taslimi,
Y., Doustdari, F., Salmanian, A. H.,
and Rafati, S. (2004). Immuniza-
tion with the hybrid protein vac-
cine, consisting of Leishmania major
cysteine proteinases Type I (CPB)
and Type II (CPA), partially pro-
tects against leishmaniasis. Vaccine
22, 1930–1940.
Zambrano-Villa, S., Borjas, D., Car-
rero, J., and Ortiz-Ortiz, L. (2002).
How protozoan parasites evade the
immune response. Trends Parasitol.
18, 272–278.
Zhu, Q., Egelston, C., Vivekanandhan,
A., Uematsu, S., Akira, S., Klinman,
D.M.,Belyakov, I.M., andBerzofsky,
J. A. (2008). Toll-like receptor lig-
ands synergize through distinct den-
dritic cell pathways to induce T cell
responses: implications for vaccines.
Proc. Natl. Acad. Sci. U.S.A. 105,
16260–16265.
Zijlstra, E. E., el-Hassan, A. M., Ismael,
A., and Ghalib, H. W. (1994).
Endemic kala-azar in eastern Sudan:
a longitudinal study on the incidence
of clinical and subclinical infection
and post-kala-azar dermal leishma-
niasis. Am. J. Trop. Med. Hyg. 51,
826–836.
Zwingenberger, K., Harms, G., Pedrosa,
C., Omena, S., Sandkamp, B., and
Neifer, S. (1990). Determinants
of the immune response in vis-
ceral leishmaniasis: evidence for
predominance of endogenous
interleukin 4 over interferon-
gamma production. Clin. Immunol.
Immunopathol. 57, 242–249.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 05 January 2012; accepted: 14
April 2012; published online: 15 May
2012.
Citation: Das A and Ali N (2012)
Vaccine development against Leishma-
nia donovani. Front. Immun. 3:99. doi:
10.3389/ﬁmmu.2012.00099
This article was submitted to Frontiers
in Microbial Immunology, a specialty of
Frontiers in Immunology.
Copyright © 2012 Das and Ali. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org May 2012 | Volume 3 | Article 99 | 19
